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ABSTRACT 
 Antibiotics are one of the most beneficial discoveries in medicine and 
public health.  However, the use, overuse, and misuse of these drugs have led to 
increases in antibiotic resistant bacterial infections (ARI).   Furthermore, previous 
epidemiological studies have linked antibiotic use to breast cancer, but these 
studies have not included effects on metabolic organs, such as the liver and 
kidneys.  This dissertation investigates the role of antibiotic use in infections and 
liver and kidney cancers in the state of South Carolina.  Using ecological study 
methods and Poisson regression to determine relative risk ratios, it was found 
that antibiotic use is a risk factor for the development of ARIs and kidney cancer, 
but not liver cancer.  Census tracts with higher percentages of black populations 
were found to be more at risk for these outcomes, including liver cancer.  Case-
control methodology was used to investigate individual risk for liver and kidney 
cancer outcomes, and demographic and geographic variables were examined as 
confounders or effect modifiers between these relationships.  Using conditional 
logistic regression to calculate odds ratios (OR), it was determined that antibiotic 
usage is not a risk factor for liver cancer, with ORs of 1.07 (0.77-1.49) for 5 to 36 
total prescriptions, 1.33 (0.72-1.46) for 64 to 204 total prescriptions, and 1.39 
(0.98-1.98) for 205 to 4374 total prescriptions per participant.  No association 
was found between liver cancer and days of use of antibiotics, nor was their 
increased risk by specific antibiotic classes.  Despite these findings, antibiotic
vi 
 usage was associated with higher odds of kidney cancer outcomes, with ORs of 
1.50 (1.27-1.78) for 18 to 131 total prescriptions and 1.43 (1.20-1.69) for 132 to 
12362 total prescriptions per participant.  For days of use of antibiotics, ORs 
were 1.41 (1.20-1.67) for 116 to 950 total days of use, and 1.46 (1.23-1.73) for 
951 to 123588 total days of use per participant.  Also, increased kidney cancers 
risks were associated with certain classes of antibiotics for some or all levels of 
exposure by total prescription number and days of use.  Overall, these findings 
suggest that antibiotics must be used in a more judicious manner in medical 
settings
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CHAPTER 1 
INTRODUCTION 
Statement of the Problem 
Antibiotic resistant bacterial infections are responsible for approximately 
one third of intensive care unit and hospital acquired infections (1-4).  Due to the 
widespread and conventional use of antibiotics, it has become increasingly 
common to isolate resistant and multi-drug resistant organisms from patients who 
would have normally hosted susceptible bacteria.  While this trend increases, the 
utility and effectiveness of our present stock of antibiotics dwindles (5), allowing 
for an unchecked emergence of these infections.  Prudent use of antibiotics can 
help curb this trend, but in order to do so, patterns of antibiotic usage must be 
determined.  These patterns can be studied in relation to resistant infections, but 
also spatially, allowing for a bigger picture of antibiotic prescribing practices.  
This research will provide a basis for understanding traditional antibiotic usage 
against a backdrop of various demographic and geographic factors, and may 
lead to strategies for a more judicious and mindful use of antimicrobial drugs. 
Furthermore, a paucity of literature currently exists examining the 
association between antibiotic usage and cancers.  To date, only two studies 
have been published investigating this link, and both studies focused on antibiotic 
utilization and breast cancer (6;7).  While both studies demonstrated that 
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antibiotics may indeed be a risk for breast cancer, no other cancer has been 
studied in relation to antibiotics.  Physiologically, the liver and kidneys experience 
the most exposure to drugs in the bloodstream, and therefore would presumably 
carry a substantial amount of risk for antibiotic induced cancers.  Additionally, in 
respect to liver and kidney cancer, the American Cancer Society predicts rising 
numbers of cases and deaths attributable to each of these cancers from 2011 to 
2012 (8;9).  It is feasible that this upward trend may result from the inappropriate 
or excessive intake of antibiotics by these individuals.  This study aims to fill the 
gaps in the research regarding antibiotic usage and its relationship to cancer, as 
well as to examine antibiotic usage as a further risk factor for liver and kidney 
cancer.     
Background 
The overuse of antibiotics as chemotherapeutic treatments for bacterial 
infections poses serious public health care concerns.  It has been shown, many 
times over, that antibiotics are being prescribed inappropriately and excessively 
in the medical fields (10-14).  The reasons for this include physician ignorance, 
patient pressures, or inadequate examination times (15-18).  Overuse of 
antibiotics is the main driving force behind the recent emergence of antibiotic 
resistant bacterial infections (19;20).  Bacteria have the ability to rapidly evolve, 
acquiring mutations and drug resistant genes from other bacterial populations, 
allowing them to quickly overcome pharmaceuticals we depend on for therapies.  
To compound the situation, new antibiotic development has stalled, decreasing 
the stock of effective antibiotics medicine has to offer to fight these resistant 
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infections (5).  Furthermore, the use of antibiotics in the veterinary and 
agriculture fields continue to expose humans to these drugs (21-24).  Antibiotic 
usage and prescribing patterns vary geographically, as it has been shown that 
antibiotics are prescribed more often in urban areas and communities with higher 
population densities (25-27).  They can also be isolated more readily from 
farming, agriculture, aquaculture, and coastal ecosystems (28;29).  These spatial 
differences in exposures to antibiotics must be described and understand to 
prevent potential adverse outcomes to public health.     
In addition, antibiotics are very powerful drugs and have many known 
adverse side affects.  These range from relatively mild, even asymptomatic, 
reactions to serious and life threatening conditions.  Some of the most serious 
include toxicities of the body’s organs or organ systems resulting in use of 
antibiotics (30;31).  Among the organs within the body, the liver and kidneys play 
the lead role in metabolizing and excreting chemotherapeutics, and are therefore 
prone to developing toxicities (32-36).  Although toxicities can be induced by 
antibiotics, it is feasible that even more serious complications can arise.  Studies 
by Knekt (7) and Velicer (6) have shown associations between treatment of 
women with antibiotics and breast cancer, showing that these chemotherapeutics 
may have a much more serious role in disease development.  Associations 
between bacterial infections and various cancers have also been uncovered.  For 
example, infections with Streptococcus bovis have been associated with colon 
cancer, Helicobacter pylori with gastric cancer, and Salmonella typhi with 
gallbladder.  However, the studies by Knekt and Velicer have ruled out initial 
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bacterial infection as risk factors for cancer, but rather that the subsequent 
consumption of antibiotics confers the actual risk.   
The American Cancer Society reported that in 2011, an estimated 26,190 
cases of liver and intrahepatic bile duct cancer occurred resulting in 6,330 deaths 
in the Unites States (9).  It is expected in 2012 that there will be a total number of 
28,720 cases and 6,570 deaths (8).  Additionally, in 2011, 60,920 cases of 
kidney and renal pelvis cancer were reported, leading to 13,120 deaths (9).   It is 
estimated that in 2012, 64,770 cases will be reported and will result in 13,570 
deaths (8).  Both of these types of cancers display increasing trends in cases 
reported and resulting deaths.  Moreover, the literature points to elevated risks of 
liver and kidney cancers in certain ethnicities and genders, the highest risks 
found in African Americans and men. Determining and understanding the 
etiologies behind these trends, the role of antibiotic usage in relation to liver and 
kidney cancers, and cancer disparities among populations may provide insight 
into more cautious prescribing of antibiotics.    
Proposal and Specific Aims 
Using both ecological and case control studies, I propose to study 
antibiotic usage and its effects on antibiotic resistant bacterial infections, as well 
as its relationship with liver and kidney cancers in South Carolina.  First, 
antibiotic usage or antibiotic prescription rates will be determined for various 
demographic aspects and geographic variables in the state.  This will yield 
information regarding state wide antibiotic usage practices and provide the 
foundation for the associations between resistant infections and cancer.  Next, 
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the frequencies antibiotic resistant bacterial infections will be examined in relation 
to antibiotic utilization rates.  Cases of liver and kidney cancers in South Carolina 
can be linked to both rates of antibiotic usage and resistant bacterial infections in 
this way.  These investigations will be accomplished by appending Medicaid 
administrative claims data this State Health Plan (SHP) claims data and linking 
this to data from the South Carolina Central Cancer Registry (SCCCR).  This 
data linkage between Medicaid and SHP to SCCCR databases is unique to this 
study, as this type of linkage is not possible in other states. 
Additionally, based on analyses by Velicer et al, separate case control 
studies will be performed to determine the association between antibiotic usage 
and liver and kidney cancers, respectively.  Velicer’s study was focused on 
breast cancer, and therefore women over age 19 years were the focus of the 
study (n = 10,219).  Cases (n = 2,266) presented with primary, invasive breast 
cancer, and were enrolled at Group Health Cooperative (GHC) for at least one 
year.  Controls (n = 7,953) were randomly selected and frequency matched to 
cases based on age and length of enrollment in GHC (6).  For the liver and 
kidney cancer aims in this exploration, my study population will again focus on 
male and female Medicaid and SHP recipients and cases of cancer for both 
genders will be ascertained from SCCCR.  South Carolina provides a distinctive 
and ideal location in which to perform these studies due to its large rural 
population and geographically diverse regions.  Of the two studies that have 
examined the relationship between cancer and antibiotic usage, neither has 
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addressed disparities among gender or different population types, which is a goal 
of this study.   
Therefore, the specific aims of this investigation follow: 
 To describe antibiotic usage and patterns, antibiotic resistant bacterial 
infections, and cases of liver and kidney cancers in South Carolina using 
ecological study methodologies and Medicaid and SHP administrative 
claims data linked with SCCCR data.  These associations will be 
investigated against the background of various demographic and 
geographic factors. 
 To evaluate the association, overall, by gender, and by population type, 
between antibiotic usage and the risk of liver cancer among Medicaid and 
SHP recipients and individuals registered in SCCCR.  Due to the inherent 
toxicity of antibiotics and the role of the liver during drug metabolism, this 
analysis may provide outcome based perspectives and strategies for the 
use of antibiotics.  
 To evaluate the association, overall, by gender, and by population type 
between antibiotic usage and the risk of kidney cancer among Medicaid 
and SHP recipients and individuals registered in SCCCR.  Due to the 
inherent toxicity of antibiotics and the role of the kidneys during drug 
excretion, this analysis may provide outcome based perspectives and 
strategies for the use of antibiotics. 
These analyses strive to not only understand the effects of antibiotic 
usage on resistant infections and cancers, but also to uncover the antibiotic 
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prescribing patterns and practices for the state of South Carolina.  When these 
rates are further described in combination with infections and cancer cases, it 
can be determined if antibiotics are risk factors for or driving forces behind these 
diseases.        
Significance of Research 
The overuse of antibiotics has become problematic around the world 
(12;13;19;37;38).  These irresponsible and immoderate practices have ushered 
in an era of increasing frequencies of antibiotic resistant infections and may lead 
to more serious risks including cancer.  It is important to understand the effects of 
antibiotic overuse in response to bacterial infections, as the use of these drugs 
act as an impetus for the selection of antibiotic resistant bacteria.  Infections 
caused by these types of bacteria require much more intensive and complicated 
treatments, placing patients in even more reduced states of health and resulting 
in economic losses (13;14).  This investigation seeks to temper the antibiotic 
overuse-bacterial resistance cycle by elucidating aspects of the primary cause, 
rates of antibiotic usage and prescribing in South Carolina. 
Additionally, only two studies have examined the association between the 
utilization of antibiotics and its role in the development of cancers to date.  Yet 
neither study examines the risk of other cancers besides breast cancer.  This 
investigation aims to bridge the gap in this knowledge by expanding previous 
methodologies to liver and kidney cancers.  As these organs are responsible for 
the majority of drug metabolism and excretion, it is biologically plausible that they 
would be targeted for negative effects from circulating antibiotics in the 
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bloodstream.  Case control studies which examine the association between 
antibiotic utilization and liver and kidney cancers will clarify the role of antibiotics 
as risk factors for cancer, and will provide medical and clinical insight into a more 
appropriate and moderate use of these drugs.  
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CHAPTER 2 
MATERIALS AND METHODS 
Overall Study 
Data Sources: 
This study will use existing demographic and pharmacy data and 
diagnostic codes from South Carolina Medicaid administrative claims merged 
with State Health Plan (SHP) claims data.  Specifically, pharmacy or drug files 
from Medicaid and SHP will be used to ascertain antibiotic prescribing data.  
These appended datasets will also be integrated with liver and kidney cancer 
incidences from the South Carolina Central Cancer Registry (SCCCR).  The 
study period includes dates from January 1, 2000 to December 31, 2009.  These 
data will be linked by unique patient identification numbers, but personal data will 
not be used in this analysis, with the exception of geocoding.  Geocoding will be 
performed at the South Carolina Budget and Control’s Office of Research and 
Statistics.  Researchers and investigators at the University of South Carolina will 
not have access to protected health information used for geocoding.  Geocoding 
of the patient records will provide data for antibiotic usage, antibiotic resistant 
bacterial infections, and cancer incidences.  United States Census Bureau data 
will be used to determine geographical aspects of the state of South Carolina, 
including numbers and locations of rural and urban areas, metropolitan 
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city centers, and population densities.  Coastal areas will be defined by the U.S. 
Census fixed distance inland boundary of 50 miles from the coast to inland.  
Interior areas will range from 51 miles from the coast to the inland border of the 
state.  
Inclusion Criteria: 
Study participants will represent both males and females aged 18 years or 
older.  This restricts the dataset to adults only.  All participants will be selected 
from patients enrolled in Medicaid or SHP continuously for at least 1 year before 
the diagnosis of liver or kidney cancer.  Furthermore, all participants in this study 
must have an existing address to allow for geocoding.  In some cases, if 
individuals have two or more different addresses during the study period, the 
address of the longest residence will be utilized for this study. 
Antibiotic Usage: 
Antibiotic usage will be assessed by using Medicaid and SHP data.  This 
study will be limited to antimicrobial agents effective against bacterial infections 
and will exclude antiviral, antifungal, and antiparasitic agents.  Variables in the 
Medicaid Pharmacy file include: date dispensed, class of drug, national drug 
code (NDC), quantity, number of refills, days supplied, and therapeutic class.  
Variables in the SHP drug file include: date written, days of therapy, date 
dispensed, NDC, and drug strength.  Two measures of antibiotic usage can be 
used, but both will have to be adjusted for the time the participant was enrolled in 
Medicaid or SHP.  The first measure will be indicated primarily by the cumulative 
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days of antibiotic usage during the study period.  This will be indicated by the 
days supplied variable in Medicaid and the days of therapy variable in SHP.  
These values will then be summed up for each participant to generate the 
cumulative days of antibiotic use.  Alternatively, this measure can be calculated 
by dividing the quantity of antibiotic prescribed by the quantity intended to be 
taken per day.  In addition to cumulatively summing up days of use per 
participant, they can be summed up separately for each of the most common 
classes of antibiotics prescribed for study participants (for example, macrolides, 
tetracyclines, penicillins, cephalosporins, sulfonamides, and nitrofurantoins).  
Days of cumulative use categories will include: 0 days, 1 to 50 days, 51 to 100 
days, 101 to 500 days, 501 to 1000 days, and more than 1001 days.  The other 
measure of antibiotic usage is the total number of antibiotic prescriptions per 
participant during the study period.    Total number of prescription categories will 
include: 0 prescriptions, 1 to 5 prescriptions, 6 to 10 prescriptions, 11 to 15 
prescriptions, 16 to 20 prescriptions, and more than 20 prescriptions.     
Ascertainment of Antibiotic Resistant Bacterial Infections:  The cases of antibiotic 
resistant bacterial infections will be ascertained from ICD-9 codes for resistant 
infections from Medicaid administrative claims and SHP administrative claims 
data.  These codes include: V09.8 infection with microorganisms resistant to 
other specified drugs, 041.12 methicillin resistant Staphylococcus aureus, V09.0 
infection with microorganisms resistant to penicillins, V09.2 infection with 
microorganisms resistant to macrolides, V09.3 infection with microorganisms to 
tetracyclines, V09.4 infection with microorganisms resistant to aminoglycosides, 
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V09.6 infection with microorganisms resistant to sulfonamides, 038.12 methicillin 
resistant Staphylococcus aureus septicemia, and 482.42 methicillin resistant 
pneumonia due to Staphylococcus aureus. 
Selection of Liver and Kidney Cancer Cases and Controls: 
Cases of liver and kidney cancer will be ascertained from SCCCR.  
Primary liver cancer cases, including hepatocellular carcinoma and bile duct 
carcinomas will be included.  Kidney cancers will include renal cell carcinomas 
and renal pelvis cancers.  Incidence density sampling will be used as controls will 
be randomly selected from Medicaid and SHP enrollees during the same years 
the cases were diagnosed.  Controls will be frequency matched to cases at a 
ratio of 3:1 on birth year, by 2 year intervals, and duration of enrollment in 
Medicaid or SHP with pharmacy records availability (≤ 2 years, 3 – 6 years, 7 – 
10 years, and ≥ 11 years of enrollment).  Frequency matching will ensure that the 
characteristics of the population of controls are similar to the characteristics of 
the cases.  
Assessment of Other Risk Factors: 
Known and suspected risk factors for liver and kidney cancer include age, 
sex, race, smoking, liver cirrhosis, co-infections, and alcohol consumption.  
Information on these factors will be obtained from Medicaid and SHP 
administrative claims data or from SCCCR data, if possible. 
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Specific Aim #1:  Antibiotic Usage Patterns in Relation to Resistant 
Bacterial Infections and Liver and Kidney Cancer Cases 
Objective: 
The objective of this study is to describe antibiotic usage in the state of 
South Carolina in respect to a variety of geographical and population based 
factors.  Antibiotic usage will be reflected by either the number of antibiotic 
prescriptions or the cumulative days of antibiotic usage during the study period.  
Antibiotic resistant bacterial infections and cancer outcomes can then be 
described against antibiotic usage patterns. 
Methodology: 
Exposure data will be ascertained from Medicaid and SHP pharmacy and 
drug files and outcome data will be ascertained from SCCCR data.  Antibiotic 
usage will be summed for each census tract, using either number of cumulative 
prescriptions or days of use for the exposure variable.  The exposure variable will 
be divided into tertiles of exposure, low, medium, and high.  Infections, liver 
cancer, and kidney cancer cases will also be summed by census tract for the 
outcomes.  Census tracts will be classified based on demographic and 
geographic criteria from United States Census Bureau data from the year 2000 
and Department of Natural Resources data.  Multivariate Poisson regression with 
standard errors will be used to ascertain incidence rate ratios, which will be used 
as estimates for relative rate ratios.  Only significant variables will be included in 
the multivariate model.  This will allow for the determination of important 
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demographic and geographic factors in relation to prescribing patterns of 
antibiotics in the state of South Carolina.  Data retrieval, management, and 
analyses will be performed using SAS version 9.2 (SAS Institute Inc., Cary, NC) 
and P < 0.05 will be used to determine statistical significance. 
Specific Aims #2 and #3:  Liver and Kidney Cancer Case-control Studies 
Objective: 
The objectives of these studies are to describe and assess the association 
between the use of antibiotics and liver and kidney cancer outcomes.  This will 
be assessed overall, by class of antibiotic, sex, and varying population type.  The 
data will be stratified by the most commonly used classes of antibiotics in the 
dataset.  Associations will be described for males and females separately, for 
urban and rural populations, as well as by counties in relation to low or high 
minority populations within the county itself.  Further analyses may be carried out 
based on the stratification of other variables in the dataset.    
Statistical Analyses: 
Conditional logistic regression will be used to estimate the odds ratios of 
liver and kidney cancer associated with antibiotic use overall, by antibiotic class, 
sex, and population type.  Calculating odds ratios by class of antibiotic will allow 
for ascertainment of cancer risk by type of antibiotic, as one class may be 
associated more strongly than another with a cancer outcome.  Furthermore, 
odds ratios will be calculated separately by sex and population to examine any 
gender or geographic disparities that may exist between the association between 
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antibiotic usage and cancer outcomes.  The cancer outcome variable will be 
categorical, either yes (1) or no (0), while the predictor variable of days of 
antibiotic use or number of prescriptions will be continuous.  All logistic 
regression analyses will be adjusted for the matching variables (age, length of 
enrollment in Medicaid and SHP, etc.), which will be modeled as continuous 
variables.  Data retrieval, management, and analyses will be performed using 
SAS version 9.2 (SAS Institute Inc., Cary, NC) and P < 0.05 will be used to 
determine statistical significance.
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CHAPTER 3 
LITERATURE REVIEW 
Part I.  Antibiotic Toxicity and Metabolism 
 Antibiotics are traditionally defined as naturally occurring agents that have 
microbicidal or microbiostatic activity, but also include semi-synthetic, or 
synthetic agents with these actions (1;2). In general, antibiotics, also referred to 
as antimicrobials, provide positive outcomes for the majority of patients, offering 
relatively quick and easy treatments for a myriad of infectious diseases.  
However, despite the success of these drugs, they also pose risks to patients 
because of their many associated side effects and adverse reactions.  Some of 
these effects can be relatively mild and even unknown to the patient, whereas 
other effects can be life threatening.  These include anaphylaxis, organ toxicities, 
including those of the ears, liver, and kidneys, cardiac arrhythmias, and seizures 
(3;4).  In fact, approximately 25% of adverse reactions seen in hospitalized 
patients arise from the use of antibiotics.  Antibiotic related side effects also have 
economic impacts to patients, as nephrotoxicities due to vancomycins and 
aminoglycosides can add up to $2,500 per patient with this toxicity (5).  These 
costs can continue to climb if patients must stay longer in the hospital or receive 
more advanced and specialized therapies to treat antibiotic induced adverse 
reactions (6).
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Five primary mechanisms of antibiotic toxicity can be described.  Direct 
effects on tissues can occur due to interactions between the drug and or the 
drug’s metabolites on a particular tissue or organ within the body (4).  These are 
in part due to the chemical and molecular structures of the antibiotics, the body’s 
own immune responses to and formation of toxic anti-metabolites from antibiotics 
(3).  Examples of direct effects include anemias caused by chloramphenicols and 
nerve toxicities, resulting in deafness and vertigo, due to aminoglycosides.  
Hypersensitivities, and specifically type I hypersensitivity, are responsible for 
anaphylaxis due to antibiotics, and result from individuals’ own genetic 
predispositions to these agents (3).  These can include certain types of anemias, 
serum sickness, and other allergic syndromes.  Changes in the patient’s 
microbial flora may predispose them to adverse reactions, such as fungal 
infections by Candida or Aspergillus.  When using antibiotics, and especially 
broad spectrum antibiotics, much of the host’s normal microflora is eliminated.  
This allows opportunistic species of fungus, as well as bacteria, to colonize and 
infect susceptible individuals.  In many cases, drug interactions can be the cause 
of toxicities.  When two or more drugs are taken in combination, regardless of 
their classes or purposes, interactions are always possible.  Sometimes, the 
interactions can be relatively harmless to the patient and merely result in the 
inactivation of one or both of the drugs.  In other cases, severe toxicities can 
occur from combinations of pharmaceuticals.  For example, the use of 
furosemide, used to treat high blood pressure, in conjunction with cephaloridine 
can lead to kidney toxicity.  Lastly, upon treatment with antibiotics, microbial cells 
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may lyse and release toxic products and components from the cell.  These toxins 
are capable of producing secondary conditions, including erythema nodosum 
leprosum, seen in about 50% of lepromatous leprosy patients treated with 
dapsone, and Jarisch-Herxheimer reactions, which result from treatment of 
neurosyphilis with intravenous penicillin (4).  It can be noted that many of these 
side affects can be attributed to a particular class of antibiotics, or even a specific 
antibiotic.  To illustrate, trovafloxacin and temafloxin were found to be 
responsible for hepatotoxicity and hemolysis, respectively.  Due to the severity 
and high incidence of these toxicities, deaths from trovafloxacin and an incidence 
of toxicity in 1 of every 3500 patients treated with temafloxacin, these antibiotics 
were removed from the market.  Despite the withdrawal of the most toxic 
antibiotics from pharmaceutical circulation, many antibiotics remaining on the 
market or in development and clinical trail phases do possess certain, deemed 
appropriate, levels of toxicities (3).        
Antibiotic Metabolism and Effects on the Liver and Kidneys 
The liver and kidneys play vital roles in the metabolism and excretion of 
pharmaceuticals, including antibiotics.  Due to these roles, these organs are 
usually associated with antibiotic induced toxicities.  The liver is the most 
metabolically active tissue per unit of weight, and is therefore responsible for the 
bulk of drug metabolism.  In addition to its metabolic activities, the liver is also the 
largest organ in the body, is perfused by blood containing drugs from the 
digestive tract, and houses the majority of drug metabolizing enzymes found in 
organs of the body, further cementing its vast role in drug metabolism.  The liver 
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accomplishes two phases of drug metabolism, and depending on the drug, both 
of these phases will be completed in sequence, or only one of the two phases will 
be performed.  Phase 1 reactions include oxidation, reduction, and hydrolysis of 
the drug which prepares it for the second phase to produce conjugation products.  
Phase 2 conjugation reactions, which include glucoronidation, sulphation, and 
acetylation, increase the water solubility of the drug permitting its excretion in bile 
or urine.  Phase 2 reactions can also inactivate the drug or its active metabolites 
produced in phase 1 (7;8).  Various factors influence the rate of drug metabolism 
by the liver.  Age, sex, host microflora, nutrition, circulation pathways, genetic 
predispositions, and drug interactions have all been shown to affect drug 
metabolism (7).   
Drug induced liver injury (DILI) causes most cases of liver failure seen in 
the United States, composing 13% of these cases (9), but severe antibiotic 
caused hepatotoxicities are relatively rare, occurring in less than 5 people per 
100,000 per year (10).  Usually, antibiotic induced hepatotoxicity is 
asymptomatic, causing mild liver impairment, and resolves on its own.  In a few 
cases, it can be more serious, requiring the need for a liver transplant or can lead 
to death resulting from liver failure (11;12).  The majority of antibiotic induced 
hepatotoxicity cases can be classified as idiosyncratic, meaning that the 
condition is host specific, occurs in a small population of those treated, and 
cannot be predicted from the antibiotic’s pharmacology or pre-clinical toxicology 
testing (13).  Most of the time, causes of DILI are poorly understood and rather 
vague, but studies have shown that 45.5% of cases are caused by antibiotics 
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and that this is the largest class of therapeutic agents associated with DILI (9) 
and liver biopsies (14).  However, predisposing factors, such as age, pre-existing 
liver disease, use of other drugs, bacterial infections, and alcohol consumption 
can influence a patient’s susceptibility to DILI (15).  Furthermore, dosage of the 
antibiotic is related to development of DILI.  Drugs administered in greater than 
50 mg/day resulted in 77% of cases of DILI in a Swedish study (16). 
 The kidneys not only mediate drug excretion but also play a role in the 
metabolism of drugs.  Studies have shown that the kidneys carry out certain 
metabolic functions at a faster rate than the liver (17-19), and its metabolic 
repertoire has thus expanded in the past few decades.  The kidneys receive a 
large amount of blood during circulation, about 25% of resting cardiac output (20) 
and are therefore routinely and directly exposed to drugs and compounds in the 
bloodstream (19).  Biochemical reactions in the kidneys, which include the same 
types of phase 1 and phase 2 reactions that occur in the liver, are capable of 
activating or inactivating drug compounds and may produce metabolic 
byproducts which are toxic to the organ.  Blood flow through the kidneys, the pH 
of urine, and urine filtration pathways provide increased concentrations of drugs 
in various sections of the kidney, which may subsequently lead to damage of the 
organ (21). 
 Drug induced nephrotoxicities are moderately common sources of kidney 
injury, with the incidence of drug induced nephrotoxicity as high as 66% in the 
elderly population.  Different classes of antibiotics can cause various effects on 
the structure and function of kidneys which can lead to injury.  For example, 
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aminoglycosides are accountable for tubular cell toxicities.  This class of 
antibiotics are toxic to renal tubular cells because of their continuous role in 
concentrating and absorbing filtrate, thus exposing them to higher concentrations 
of the antibiotic.  Many classes of antibiotics, including vancomycins, quinolones, 
beta lactams, and sulfonamides, are responsible for acute interstitial nephritis.  
These drugs bind antigens, or can even act as antigens, and are then deposited 
in the interstitium, the extravascular space surrounding the tubules (22), of the 
kidney causing an immune reaction.  Exposure to some antibiotics, such as 
ciprofloxacins and sulfonamides, can result in crystal nephropathies, which is the 
production of urine insoluble crystals in the kidneys leading to impairment of 
function (20;23).  While certain antibiotics are inherently nephrotoxic, some 
produce damage because of prolonged treatment with the drug or in a dose 
dependent manner (24).  Patient risk factors for drug induced nephrotoxicities 
include age over 60 years, underlying kidney conditions, diabetes, and heart 
failure.  Certain types of bacterial infections are also associated with antibiotic 
induced nephrotoxicity, as Gram negative bacterial sepsis treated with 
aminoglycosides have been shown to result in nephrotoxicity in 10% to 20% of 
cases (25). 
Part II.  Antibiotic Usage and Trends 
 The past few decades have shown a marked increase in the global use of 
antibiotics in hospital and outpatient settings in both public and private sectors 
(26-29).  Data from the National Ambulatory Medical Care Survey and the 
National Hospital Ambulatory Medical Care Survey show that prescriptions of 
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some classes of antibiotics have increased by shocking rates.  In just the 1990’s, 
the use of azithromycin and clarithromycin increased by 388%, quinolones by 
78%, and amoxicillin and clavulanate by 72% (30).  This increase stems from a 
number of reasons, the most bothersome being that physicians will prescribe 
antibiotics to patients merely because they feel the patient wants or expects them 
or that it will reduce return visits (31).  For example, antibiotics are prescribed to 
approximately 75% of adults with acute pharyngitis, or sore throat (32).  In these 
cases, physicians report that they do so because they believe the patient expects 
them, the patient will be unsatisfied or come back if not given a prescription, or 
that it is easier to write a prescription than to explain why the patient’s condition 
does not require an antibiotic (33-35).  Further studies have shown that 
prescriptions of antibiotics lend a heightened level of credibility to the patient’s 
illness and that they will subsequently be more likely to return in the future with a 
similar illness and expect another prescription (36-38).   
 In the United States, otitis media is the most common complaint for the 
administration of antibiotics in children.  This includes a second prescription of 
antibiotics after the initial treatment.  Differences in rates of repeat prescriptions 
were observed depending on the cost of the initial antibiotic used.  Pediatric 
Medicaid populations showed that a repeat treatment occurred in 11.6% of 
children when a less expensive antibiotic was used compared to 13.2% when a 
more expensive antibiotic was used (39).  Parents are often driving forces when 
it comes to antibiotic prescriptions, as physicians are more likely to prescribe 
antibiotics to a child if that is their parents’ wish (40).  Yet, by educating parents 
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about the judicious use of antibiotics, numbers of prescriptions can decrease.  A 
two year randomized trial in Massachusetts and northern Washington showed 
that antibiotic prescribing rates dropped by 15% in groups of children aged 36 
months to less than 72 months when their parents were educated about 
appropriate antibiotic use opposed to 9.8% in the control group.  Prescribing 
rates for children between 3 months to less than 36 months were reduced by 
18.6% in the treatment group and 11.5% in the control group (41).  
 Canadian and American studies have determined that up to 50% of 
antibiotic prescriptions are unnecessary or inappropriate for which they are 
prescribed (42;43).  In the United States, about 75% of antibiotics prescribed on 
an outpatient basis are for five different respiratory infections, including otitis 
media, sinusitis, pharyngitis, bronchitis, and generic upper respiratory tract 
infections (44). Moreover, the majority of these prescriptions are viewed as 
unnecessary, as most of these infections are viral in nature or the use of 
antibiotics would not provide any clinical effects (32;45).  An alarming 55% of the 
antibiotics prescribed for the respiratory infections described above are deemed 
excessive, costing an excess of $726 million a year (44). 
   Globally, antibiotic prescribing is also on the rise, as antibiotic usage in 
India remains high due to the improper use of these drugs and a lack of 
knowledge about the primary benefits and outcomes due to antibiotics (46).  High 
rates of broad spectrum antibiotics and newer classes of antibiotics are being 
prescribed in India, especially by public clinics and pharmacies.  It was shown 
that 39% of patients at a public clinic or retail pharmacy were prescribed at least 
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one antibiotic, and 43% of patients attending private clinics left with at lease one 
antibiotic prescription (26).  Antibiotic use in Dutch hospitals was shown to rise 
because of an increased duration in hospital stay and the use of more intensive 
treatments to discharge patients earlier.  It was noted in these hospitals that 
prescriptions of co-amoxiclav increased the most and that there were aberrations 
to the usual prescribing patterns of cephalosporins (47).  European studies have 
showed variable rates of antibiotic prescriptions in 26 different study countries.  
While France had the highest rate of prescriptions, a shift was also noticed from 
the older broad spectrum antibiotics to new broad spectrum drugs.  Furthermore, 
seasonal fluctuations caused marked increases in antibiotics in countries which 
already had high rates of antibiotic usage (48). 
 It is also important to note the usage of antibiotics in the dental and 
veterinary fields.  Roughly 7% to 10% of antibiotic prescriptions occur due to 
dental treatments (49).  In a 2001 British study, researchers found that 75% of 
patients attending emergency dental clinics were prescribed antibiotics 
inappropriately.  This was due to poor understandings of the pathologies of 
dental infections or the lack of knowledge about the indications of the use of 
antibiotics by the prescribing dentists.  In addition, these clinics saw large 
number of patients, which lead to shorter appointment times, perhaps hindering a 
proper diagnosis and treatment strategy by the dentist (50). 
 Veterinary antibiotics are used for the same purposes in animals as in 
humans, to prevent and treat infectious diseases.  In fact, the same classes of 
antibiotics used to treat humans can also be used to treat dogs, cats, pigs, and 
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horses (1).  However, 30% to 90% of these antibiotics are excreted by these 
animals in their active forms, ending up in soils, groundwater, and freshwater 
ecosystems, and eventually run off into the oceans (51).  While antibiotic 
treatment strategies for animals are beyond the scope of this study, its important 
to recognize that overuse of veterinary antibiotics exposes humans to these 
drugs in their natural environments.        
Antibiotic Usage and Bacterial Resistance 
 A major reason for the increase in antibiotic prescribing rates, and also a 
primary cause for this increase, is the emergence of antibiotic resistant bacterial 
infections.  As an inherent biological process, antibacterial resistance has always 
occurred in nature, but due to the selective pressure placed upon pathogenic 
strains of bacteria by the use of antibiotics, resistance has increased in both 
speed and scope in the medical field (31).  Antibiotic resistance emerged as a 
problem shortly after the introduction of penicillin in the 1940’s (52).  This was 
brought to attention due to the many outbreaks of resistant infections in pediatric 
nurseries and maternity wards in hospitals and infections of surgical wounds 
shortly thereafter (53).  Bacteria possess a genetic arsenal with which they are 
able to overcome the detrimental effects of antibiotics.  Faced with selective 
pressures, they have evolved methods to render an antibiotic useless in a 
number of ways.  Bacteria can inactivate a drug by use of detoxifying enzymes, 
reduce the transport of the drug into the cell or expel the drug from the cell’s 
interior, acquire genetic mutations to cope with the drug, or gain resistance 
genes from other bacteria via horizontal transfer methods (52).  In addition to 
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bacterial tactics, antibiotic development in general has come to a halt, resulting in 
fewer antibiotics that are available as those which bacteria can overcome can no 
longer be used (54).  As bacteria rapidly make existing antibiotics ineffective, an 
increase in resistant infections can be observed.  Moreover, bacteria are capable 
of becoming resistant to more than one antibiotic, leading to multi-drug resistant 
bacterial strains, such as Streptococcus pneumonia (55).  These multi-drug 
resistant bacterial infections are responsible for an increase in morbidity and 
mortality in intensive care unit patients in hospitals (56). 
Trends in Antibiotic Resistant Bacterial Infections 
 The overuse of antibiotics has been linked to an increase in rates of 
bacterial resistance (57-60).  These bacteria have consequently been associated 
with an increase in the incidences of resistant bacterial infections.  Antibiotic 
resistant Gram positive organisms are increasingly causing more infections and 
they are now responsible for one third of all nosocomial infections (61).  In the 
early 2000’s, concern was placed on methicillin resistant Staphylococcus aureus 
(MRSA) and vancomycin resistant Enterococcus (VRE) species (62), and from 
1990 to 2005 there was a substantial increase in MRSA infection in the united 
States.  MRSA infections increased from 2% to 39.7% in the United States in the 
past two decades (63).  It is estimated that 79% of all nosocomially acquired 
coagulase negative Staphylococcus species are methicillin resistant (64), and 
about 43% of Staphylococcus aureus isolates from patients are methicillin 
resistant.  Most of these cases occurred in patients aged 18 to less than 50 years 
old.  These infections occurred more often in African American and Hispanic 
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patients.  Hospital onset of Staphylococcus aureus cases were more likely 
caused by MRSA, with an odds ratio of 1.58 and a confidence interval of 1.46 to 
1.70 (65).  Even in 2012, MRSA can still be viewed as a public health threat as 
the incidence of these cases continues to rise (66).  VRE infections comprise a 
large number of hospital acquired infections in the United States, causing more 
morbidity, mortality, and costs than vancomycin susceptible Enterococcus 
infections (67).  A twenty fold increase in Enterococcus isolates which were 
vancomycin resistant was seen from 1993 to 1989.  From 1990 to 1997, an 
additional 17% increase in VRE isolates was reported.  This is a sobering trend 
because prior to these increases, vancomycin was seen as the last therapeutic 
resort when all other antibiotics had failed (63). 
 In addition, infections caused by antibiotic resistant Gram negative 
microorganisms, such as members of the Enterobacteriaceae and the Klebsiella, 
Escherichia, and Pseudomonas genuses, are cause for concern as they account 
for a substantial proportion of nosocomial and bloodstream infections (7;68).  To 
illustrate this trend, approximately one-third, or 36.6%, of isolates from Ghent 
University Hospital in Ghent, Belgium were proven to be antibiotic resistant 
bacterial strains (7).  A susceptibility study performed using data from 1994 to 
2000 showed increasing resistance to commonly used antibiotics by Gram 
negative organisms.  The study looked at Gram negative isolates from 43 states 
in the United States including the District of Columbia, and found that the activity 
of most antibiotic therapeutics decreased by 6% at most over the study period.  
Furthermore, the overall susceptibility to ciprofloxacin decreased from 86% to 
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76% percent during the time of the study (69).  This trend shows that bacteria are 
becoming more adept at overcoming the bactericidal and bacteriostatic effects of 
traditional antibiotics, allowing for eventual increases in antibiotic resistant 
pathogenic bacterial populations and infections.  Much of this resistance is due to 
the exposure to previous antimicrobial drugs, either the inappropriate initial use 
of antimicrobials or the length of exposure to antibiotics prior to infection (68;70).  
Inappropriate use of antibiotics includes the utilization of an antibiotic to which 
the infecting organism is already resistant to or the use of no antibiotics at the 
inception of treatment (68).  Furthermore, an odds ratio of 1.07, with a confidence 
interval of 1.01 to 1.12, was associated with the isolation of multiply resistant 
Pseudomonas aeruginosa and total days of antibiotic treatment, whereas 
Enterobacteriaceae infections were associated with prior exposure to ampicillin 
(70).  Moreover, the recent emergence of resistant Campylobacter jejuni 
infections has led to elevated rates of global morbidity and mortality.  This is due 
to the use of antibiotics in food animals, as these agents have allowed for these 
bacteria to develop resistance to common medical antibiotics.  High rates of 
Campylobacter resistance have been seen to a number of antibiotics, including 
tetracycline, amoxicillin, ampicillin, metronidazole, and cephalosporins.  
Resistance to fluoroquinolones by Campylobacter has also emerged in the 
United States, Asia, and many European countries (71).   
 While antibiotics are used to treat infections in humans, they are also 
widely used in agriculture and farming.  Half of all antibiotics utilized in the Unites 
States are used for these purposes, as they are given to livestock, poultry, and 
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fish to aid in their growth and health (72;73).  The animals treated by antibiotics 
and the humans administering them are then more likely to select and harbor 
resistant pathogenic bacteria within their bodies.  Studies of environmental and 
intestinal microbial communities, as well as stable soil bacterial communities, 
show the presence of large amounts of antimicrobial resistant gene elements, 
even after the antibiotics have been removed (74;75).  While bacteria in these 
communities may not come into direct contact with humans, horizontal or lateral 
transfer of genes from these bacteria to human pathogens poses a real threat to 
public health (76).  In this way, antibiotic use in the agricultural domain can 
directly impact the incidence of human antibiotic resistant bacterial infections. 
Geographic Trends in Antibiotic Prescribing and Exposure 
 Many studies have pointed to various prescribing patterns for antibiotics 
based on geographic locations.  One such study in 2004 attempted to determine 
the prevalence of antibiotic resistant Escherichia coli in urban and non-urban 
areas.  Mexico, Kenya, Peru, and the Philippines were used for urban samples, 
while non-urban areas were sampled from Ghana, Zimbabwe, Venezuela, 
Curacao, Mexico, and the Philippines.  The population of the area was used as 
classification for urban and non-urban regions, as a population of at least 
150,000 inhabitants was considered urban.  It was discovered that antibiotic 
resistant infections were most common in urban populations, as resistance 
ranged anywhere from 1% to 63% to various antibiotics.  This was explained by a 
higher exposure to antibiotics in these urban areas, from both agricultural and 
medical fields (77).  Furthermore, a study in China also found that antibiotics 
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were prescribed more often in urban settings rather than rural settings.  In this 
study, researchers were sent to various locations as simulated patients to 
determine antibiotic prescribing patterns.  While none of these “patients” were 
actually sick, none described having symptoms which required antibiotics and 
none asked for antibiotics, 65% of “patients” in urban areas received a 
prescription while 55% received prescriptions on rural areas.  However, this 
study showed that more expensive and powerful antibiotics were being 
prescribed in rural areas (78).  In addition, population density is a common way 
of measuring crowding or overcrowding of an area, and studies have shown that 
areas with greater densities harbor more antibiotic resistant organisms and have 
a higher overall consumption of antibiotics than less populated areas (79). 
 Exposure to antibiotics can also vary geographically based on practices in 
the veterinary and agriculture industry.  For example, areas devoted to farming 
have much higher exposures to antibiotics.  More tetracycline is consumed by 
farm animals rather than humans on an annual basis in most developed 
countries in the world.  These antibiotics are given to animals in sub-therapeutic 
concentrations to aid in their growth, but the presence of these antibiotics in the 
ecosystem often leads to the emergence of resistant bacterial strains.  
Additionally, fruit orchards are sprayed with tetracycline and oxytetracycline to 
prevent infections with Erwinia amylovora, the cause of fire blight.  Coastal areas 
also have higher exposures to antibiotics such as tetracycline as it is used to 
treat infections in lobster, catfish, and salmon (80).  Shrimp farming operations in 
coastal areas use a variety of antibiotics including quinolones, sulfonamides, and 
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tetracyclines to prevent infection in shrimp populations (81).  Exposure to 
antibiotics in these areas is often higher than usual as soil and water can serve 
as reservoirs for these antimicrobial agents as well as resistant bacteria.          
Part III.  Antibiotic Usage and Cancer 
 The hypothesis that the use of antibiotics may increase the risk of cancer 
in humans was first suggested in 1981 by Setchell et al (82).  To date, only two 
studies in which the association between the usage of antibiotics and the 
development of cancer was examined exist, and both studies examined the risk 
of only breast cancer in relation to antibiotic usage.  The first study, conducted in 
2000 by Knekt et al in Finland, determined that women below the age of 50 years 
who were treated with antibiotics for urinary tract infections had an elevated risk 
of developing breast cancer.  The relative risk reported was 1.74 with a 95% 
confidence interval of 1.13 to 2.68.  In this study, the presence of bacteria in the 
urine, or the actual urinary infection, was not associated with the increased risk, 
pointing to the use of antibiotics as the real risk factor (83).  Limitations of this 
study included the classification of antibiotic usage as only a binary variable and 
not accounting for the different classes of antibiotics or the length of treatment 
(84). 
 The second study by Velicer et al occurred in 2004 using data from 
women enrolled at Group Health Cooperative (GHC) and the Surveillance, 
Epidemiology, and End Results cancer registry (SEER) in Washington state.  
This case control study focused on the days of treatment with various classes of 
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antibiotics and their relationships with breast cancer.  Pearson correlations 
showed that the number of antibiotic prescriptions coincided with the number of 
days of antibiotic use very well, with coefficients ranging from 0.82 to 0.91.  Days 
of antibiotic use were categorized as 0 days, 1 to 50 days, 51 to 100 days, 101 to 
500 days, 501 to 1000 days, and greater than or equal to 1000 days.  Results 
showed, for all antibiotic classes combined, elevated risks for the development of 
incident breast cancer, adjusting for age and length of enrollment in GHC.  Using 
0 days of treatment as the reference group, the odds ratios for each range of 
days, and corresponding 95% confidence intervals (CI), were: 1.45 for 1 to 50 
days (CI 1.24 to 1.69), 1.53 for 51 to 100 days (CI 1.28 to 1.83), 1.68 for 101 to 
500 days (CI 1.42 to 2.00), 2.14 for 501 to 1000 days (CI 1.60 to 2.88), and 2.07 
for 1000 days or more (CI 1.48 to 2.89).  Increased risks were also associated 
with incident breast cancer and the number of antibiotic prescriptions, as well as 
the length of antibiotic use and fatal breast cancers (84). 
 Velicer et al suggest that antibiotics increase the risk of cancer in a 
number of ways.  First, antibiotics affect the metabolism of the microflora in the 
gastrointestinal tract, allowing for inefficient or incorrect processing of 
carcinogens, chemicals, and hormones.  Antibiotics can also interfere with 
immune and inflammatory responses, permitting an increase in production of 
inflammatory cytokines, prostaglandins, and enzymes (84).  These events can 
trigger mammary cells to proceed down a carcinogenic pathway and eventually 
produce fatal cancers.             
 
 39 
Part IV.  Bacterial Infections and Cancer 
    Bacteria have been linked with cancer since the 1970’s.  Endogenous 
bacteria were thought to play a role in the development of cancers because 
microbial metabolism often produces changes in the body’s biochemistry.  
Bacterial enzymes are capable of hydrolyzing, reducing, and synthesizing a 
sizeable amount of biochemicals and carcinogens from food sources, hormones, 
and environmental chemicals.  Because the human microflora contains a vast 
amount of bacteria which interact directly with the body’s physiological 
processes, relationships between colon, breast, and stomach cancer have been 
examined.  It was hypothesized that breast cancer may be influenced by the 
bacterial production of estrogens and that diet can select for these bacteria and 
provide them with appropriate substrates.  Furthermore, stomach and colon 
cancer may be attributed to the colonization of these areas with bacteria that 
produce or metabolize high amounts of nitrates, hormones, and chemical food 
additives (85). 
 While the body’s innate bacterial population provides a cancer risk, 
exogenous infection by bacteria account for a substantial amount of cancer 
cases.  By causing chronic infections, producing toxins that can affect the 
eukaryotic cell cycle, or damaging DNA, bacteria can modify cell growth and 
promote tumorigenesis.  Furthermore, certain bacteria can manipulate the 
immune system to ignore excessive cell proliferation or to even encourage it (86).  
Currently, the American Cancer Society estimates that 20% of all cancers 
globally have origins in bacterial infections (87).  Perhaps the most prevalent 
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association is that between Helicobacter pylori infection and subsequent gastric 
cancer and mucosa associated lymphoid tissue (MALT) lymphoma.  However, 
other associations have been uncovered, including the relationships between 
Salmonella typhi and gallbladder cancer, Streptococcus bovis and colon cancer, 
and Chlamydophila pneumoniae and lung cancer (86). 
 Gastric cancer is one of the most prevalent conditions worldwide and 
infection with H. pylori increased the risk of this type of cancer by 2.2 to 20 fold 
(88-91).  Bacterial-induced increases in inflammation and cell proliferation, 
abnormal DNA methylation patterns, and cellular mutations are thought to play 
roles in the formation of cancer, but other risk factors exist, including diets which 
contain high levels of alcohol and salt (88).  The global incidence of gallbladder 
cancer (GC) is 17 million cases a year, with the highest incidence in Native 
Americans, Mexican Americans, and populations in the Andes region of South 
America (86).  Salmonella typhi and its role in gallbladder cancer was described 
in an Indian study which proved that patients who were carriers of Salmonella 
had 8.47 times the risk of developing cancer than non-carriers (92).  This 
association mirrors previous findings between Salmonella and GC (93;94).  
However, other risk factors, including gallstones, obesity, environmental 
chemicals, and chronic infection of the gallbladder can contribute to carcinomas 
(86). 
 Colorectal cancer is the third most common cancer in the Unites States 
and has been linked to a number of bacteria including Escherichia coli and 
several Streptococci species, but Streptococcus bovis is now viewed as the main 
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culprit behind this cancer.  In 1974, it was first recognized that 25% to 80% of 
patients with Streptococcus bovis infection also had colon carcinomas (95), and 
the present incidence of S. bovis associated colon cancer is between 18% to 
62% (96).  The exact bacterial mechanism which causes colorectal cancer is 
poorly understood, but it is thought that an overgrowth of the bacteria or its 
antigens play a role in tumorigenesis (86;97).  Chronic Chlamydophila 
pneumoniae and Mycoplasma infection have been associated with lung and 
prostate cancer, respectively (87;98).  Approximately 54% of males and 36% of 
women with lung carcinomas tested positive for antibodies to C. pneumoniae.  
This data reflected differences between males and females and indicated that 
males were more likely to be smokers, thus making them more susceptible to 
infections (98).  Persistent Mycoplasma genitalium or hominis infection has been 
implicated in prostate cancer as 20.5% to 37.4% of patients with cancer test 
positive for the presence of Mycoplasma in prostate tissue (87;99). 
Part V.  Cancers of the Liver and Kidneys 
Liver Cancer 
 In 2011, an estimated 26,190 cases of liver and intrahepatic bile duct 
cancer occurred resulting in 6,330 deaths in the Unites States (100).  It is 
expected in 2012 that there will be a total number of 28,720 cases and 6,570 
deaths (101).  Primary liver cancer, which does not take into account any 
secondary tumors, is the sixth most reported cancer in the world and is the third 
most common cause of cancer fatalities (102).  Based on histological typing of 
 42 
liver tumors, the most common presentation of liver neoplasms is hepatocellular 
carcinoma (HCC), but other types include childhood hepatoblastoma, adult 
cholangiocarcinoma which originates from the intrahepatic biliary ducts, and 
angiosarcoma which originates from the intrahepatic blood vessels.  Liver cancer 
is more common in men than women as men are at least 2.4 times as likely as 
women to develop this cancer (103). 
 Many risk factors for liver cancer have been elucidated.  The most 
frequent is the presence of liver cirrhosis.  Earlier diagnosis and treatment of liver 
cirrhosis has led to a decrease in mortality from this condition, which in turn has 
allowed for an increase in incidences of HCC.  Danish studies have shown that 
patients have a 59.9 fold increase in developing HCC if they present with liver 
cirrhosis as well, and a 10 fold increase in developing cholangiocarcinoma with a 
cirrhosis co-morbidity (104).  Cancer may stem from cirrhotic conditions due to 
the immense amount of regeneration of hepatic cells that must occur during this 
illness.  When these regenerations progress uncontrolled or unchecked, 
tumorigenesis may occur (105).  Furthermore, changes in hormonal states, 
ineffective metabolism of carcinogens, and differential immune statuses can 
interact with cirrhotic physiologies and lead to HCC (104). 
 Another factor in the development of liver cancer, and cirrhosis, is 
infection with hepatitis B (HBV) or hepatitis C viruses (HCV) (106).   In a global 
study, Perz et al found that 30% and 27% of liver cirrhosis was attributable to 
HBV and HCV, respectively.  In addition, 53% and 25% of HCC was attributable 
to HBV and HCV, respectively (105).  Other risk factors which may lead to HCC 
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include alcohol consumption, tobacco smoking, oral contraceptive use, diabetes, 
and diet and obesity (107).  Exposures to aflatoxins, which are toxins produced 
by fungi in the Aspergillus genus, have been associated with causing mutations 
in the DNA of hepatic cells leading to tumorigenesis, and are also considered a 
risk factor for HCC (103). 
Kidney Cancer 
 In the United States in 2011, 60,920 cases of kidney and renal pelvis 
cancer were reported, leading to 13,120 deaths (100).   It is estimated that in 
2012, 64,770 cases will be reported and will result in 13,570 deaths (101).  
Incidence rates show that this cancer affects 9 out of 100,000 people per year 
(108).  About 10% of kidney cancers occur in the renal pelvis, the upper most 
part of the ureter which drains urine from the kidney, and 90% occur in the renal 
parenchyma, the actual kidney tissue which consists of nephrons.  Cancers 
which originate from the renal parenchyma are referred to as adenocarcinomas 
or renal cell cancer (RCC) (109).  RCC is ranked 10th in cancers of males and 
14th in cancers of females.  In terms of global urological cancers, RCC is the third 
most common carcinoma following prostate and bladder cancers, yet it has the 
highest mortality rate at 40% compared to 20% from prostate and bladder 
cancers (108). Asian and Pacific Islanders in the United States have the lowest 
incidences of RCC, which reflect the low incidence of this cancer in their 
countries of origin, whereas white Hispanics have much higher incidence rates 
than their counterparts in Latin America (109).  African Americans also have a 
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10% to 20% higher incidence of RCC, but the reason behind this is not yet 
known (108).  
 Risk factors for RCC include smoking, exposure to chemical carcinogens 
such as asbestos, arsenic, organic solvents, and polycyclic aromatic 
hydrocarbons, as well as exposure to ionizing radiation.  Diabetes, high blood 
pressure, long term dialysis, obesity and diet are additional factors that place 
individuals at risk for kidney cancers (108;109).  Infection with certain viruses can 
increase the risk for RCC, as those with human immunodeficiency virus (HIV) are 
8.5 times more likely to develop this cancer compared to HIV negative 
individuals.  Infections with polyomavirus type 40, adenovirus 7, and herpes 
viruses may also increase the risk for RCC (108).  There is some evidence that 
the use of diuretic and analgesic drugs can increase the risk, as well as 
estrogens from oral contraceptives (110). 
 A strong genetic component is involved with RCC.  Von Hippel-Lindau 
(VHL) disease is caused by mutations in the VHL tumor suppressor gene.  It is 
an autosomal dominant trait which leads to a myriad of carcinomas of the central 
nervous system, retinas, pancreas, and inner ears.  40% to 60% of patients with 
VHL develop RCC, and about 30% of those patients advance to metastatic RCC 
(111).   Other types of heredity syndromes are associated with the development 
of kidney carcinomas, and all stem from chromosomal mutations which lead to 
neoplasms of the kidneys, other organs, and skin (108). 
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Conclusion 
 The overuse and over-prescription of antibiotics is a primary concern for 
many reasons.  The inherent toxicity of these drugs has been shown to produce 
negative effects in many organs of the body.  The liver and kidneys, due to their 
crucial role in metabolizing and excreting antibiotics, can develop serious 
toxicities due to treatment with antibiotics.  Furthermore, excessive use of 
antibiotics, in human and animal medicine, generates resistant strains of 
bacteria, and sometimes multiply drug resistant strains.  This is a major public 
health concern, as the traditional chemotherapeutic treatment of bacterial 
infections is becoming ineffective.  Bacterial infections have also been linked with 
certain types of cancer, and with the emergence of resistant bacteria, these 
infections are returning with a higher incidence.  The increase in these infections 
may also correlate with an increase in cancers. 
 Studies by Knekt and Velicer have shown that antibiotic usage is 
associated with the development of breast cancer.  Many biological and 
physiological processes may allow for antibiotic drugs to alter cellular growth and 
proliferation, leading to the formation of carcinomas.  It is conceivable that an 
increase in liver and kidney cancer can also be attributed to antibiotic usage, via 
the same biological mechanisms which relate to breast cancer.  The trends for 
these types of cancers have shown increases in incidence over the past few 
decades, and this increasing trend is still predicted in 2012.  Dissecting and 
understanding the associations between antibiotic usage, antibiotic resistant 
bacterial infections, and liver and kidney cancers may lead to a more judicious 
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use of antibiotics and improved strategies for antibiotic prescribing in medical and 
clinical practices.  
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CHAPTER 4 
An Ecological Study of Antibiotic Usage in South Carolina by Census Tract 
Type and Racial Composition1 
Introduction 
The past few decades have shown a marked increase in the global use of 
antibiotics in hospital and outpatient settings in both public and private sectors (1-
4).  This increase stems from a number of reasons, the most troubling being that 
physicians will prescribe antibiotics to satisfy patient desires or to reduce return 
visits (5).  Even when the cause of illness is not bacterial, doctors will prescribe 
antibiotics due to patients’ expectations, belief that patients will return for an 
unnecessary visit if no prescription is written, or because it is easier to write a 
prescription than to explain why the patient’s condition does not require an 
antibiotic (6-8).     
A major reason for the increase in antibiotic prescribing rates, and also a 
primary cause for this increase, is the emergence of antibiotic resistant bacterial 
infections.  Bacteria are becoming more adept at overcoming the bactericidal and 
bacteriostatic effects of traditional antibiotics, allowing for eventual increases in 
antibiotic resistant pathogenic bacterial populations and infections.  Much of this 
                                                           
1
 Thathiah, P., S.A. Adams, A. Merchant, R. Moran, K. Bennett, R. S. Norman.  
2014.  To be submitted to Cancer Causes and Control. 
 65 
resistance is due to the exposure to previous antimicrobial drugs, either the 
inappropriate initial use of antimicrobials or the length of exposure to antibiotics 
prior to infection (9;10).  As bacteria rapidly make existing antibiotics ineffective, 
an increase in resistant infections can be observed.  Moreover, bacteria are 
capable of becoming resistant to more than one antibiotic, leading to multi-drug 
resistant bacterial strains, such as Streptococcus pneumonia (11).  It has clearly 
been shown that the overuse and misuse of antibiotics has been linked to 
increased rates of bacterial resistance in recent medicine (12-15).   
Studies have pointed to various prescribing patterns for antibiotics based 
on geographic locations.  A study in 2004 in Mexico, Kenya, Peru and the 
Philippines discovered higher exposure to antibiotics in urban areas of these 
countries, from both agricultural and medical fields (16).  In addition, a study in 
China found that antibiotics were prescribed more often in urban settings than in 
rural settings.  However, this study showed that more expensive and powerful 
antibiotics were being prescribed in rural areas (17).  In addition, population 
density is a common way of measuring crowding or overcrowding of an area, and 
studies have shown that areas with greater densities harbor more antibiotic 
resistant organisms and have a higher overall consumption of antibiotics than 
less populated areas (18).  Exposure to antibiotics can also vary geographically 
based on practices in the veterinary and agriculture industry.  For example, areas 
devoted to farming have much higher exposures to antibiotics, as tetracyclines 
are given to animals in sub-therapeutic concentrations to aid in their growth.  
Additionally, fruit orchards are sprayed with tetracycline to prevent bacterial 
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blights.  Persons in coastal areas have higher exposures to antibiotics such as 
tetracycline used to treat infections in lobster, catfish, and salmon (19;20).  
Environmental exposure to antibiotics for persons in these areas is often higher 
than what is usually encountered in soil and water. 
In addition to the emergence of antibiotic resistant bacterial infections, 
antibiotic use has been suggested as a risk factor for human cancer.  This 
hypothesis was first proposed by Setchell et al in 1981 (21) and has gained 
credibility through studies by Knekt et al in 2000 and Velicer et al in 2004 (22;23).  
Both studies found that antibiotic usage is a risk factor for breast cancer, yet it is 
also plausible that antibiotic use has a hand in causing cancers in other organs of 
the body.  The liver and kidneys, being the major organs responsible for 
metabolizing and excreting antibiotics carry the greatest risk to be affected by 
antibiotic usage (24-30).  Using aggregated data, this study aims to determine 
the risks of developing resistant bacterial infections, liver cancer, and kidney 
cancer by accounting for exposure to antibiotic prescriptions in populations in 
various census tract types in the state of South Carolina 
Methods 
Data Sources:  This ecological study aimed to determine risk factors, specifically 
antibiotic usage and geographic and demographic factors, for outcomes of ARI, 
liver cancer, and kidney cancer at an aggregate level.  It used existing 
demographic and pharmacy data and diagnostic codes from South Carolina 
Medicaid administrative claims merged with State Health Plan (SHP) claims data.  
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Specifically, pharmacy and drug files from Medicaid and SHP were used to 
ascertain antibiotic prescribing data.  These appended datasets were integrated 
with liver and kidney cancer incidences from the South Carolina Central Cancer 
Registry (SCCCR), a division of the South Carolina Department of Health and 
Environmental Control (SCDHEC).  The study period included dates from 
January 1, 2000 to December 31, 2009.  Study participants represented both 
males and females aged 18 years or older.  This study was approved by both the 
University of South Carolina and SCDHEC Institutional Review Boards.     
Determination of Census Tract Types:  United States Census Bureau data from 
2000 and the Department of Natural Resources (DNR) GAP data and Landcover 
codes 54 were used to determine geographical aspects of the state of South 
Carolina, including racial composition of census tracts, agricultural or industrial, 
coastal or inland, and rural or urban census tract designations.  Racial 
composition was determined by the percentage of black population within each 
tract, 0 to 33%, 34 to 66%, and 67 to 100%.  Agricultural or industrial census 
tracts were determined by DNR Landcover Codes.  Industrial areas were defined 
as those with Landcover codes 22 and 23 (Urban development and Urban 
residential).  Census tracts which were more than 50% developed were classified 
as industrial.  Census tracts with less than 50% development were classified as 
agricultural.  Coastal census tracts were defined within counties in the coastal 
zone, or the counties of Beaufort, Berkeley, Charleston, Colleton, Dorchester, 
Horry, Jasper, and Georgetown.  Census tracts in all other counties were defined 
as inland.  Using census data, census tracts which had greater than or equal to 
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50% urban characteristics (urban areas with a population of 50,000 or more) 
were classified as urban, otherwise the tract was classified as rural.   
Antibiotic Usage:  Antibiotic usage was assessed by using Medicaid and SHP 
data.  This study was limited to antimicrobial agents effective against bacterial 
infections and excluded antiviral, antifungal, and antiparasitic agents, and were 
chosen by using American Hospital Formulary System (AHFS) codes.  
Furthermore, only antibiotics prescribed for oral use were included.  Topical and 
intravenous antibiotics were excluded.  Each record was geocoded, allowing for 
placement into the appropriate census tract in the state.  All antibiotic 
prescriptions during the study period were summed up by each census tract and 
the tract was later geographically and demographically defined by using the 
methods above.  
Selection of Antibiotic Resistant Bacterial Infections:  Incidences of antibiotic 
resistant infections (ARI) were determined using ICD-9 codes from Medicaid and 
SHP claims data.  These ICD-9 codes included:  V09.8 infection with 
microorganisms resistant to other specified drugs, 041.12 methicillin resistant 
Staphylococcus aureus, V09.0 infection with microorganisms resistant to 
penicillins, V09.1 infections with microorganisms resistant to cephalosporins and 
other β-lactam antibiotics, V09.2 infection with microorganisms resistant to 
macrolides, V09.3 infection with microorganisms to tetracyclines, V09.4 infection 
with microorganisms resistant to aminoglycosides, V09.5 infection with 
microorganisms resistant to quinolones and fluoroquinolones, V09.6 infection 
with microorganisms resistant to sulfonamides, 038.12 methicillin resistant 
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Staphylococcus aureus septicemia, 041.12 methicillin resistant Staphylococcus 
aureus, 482.42 methicillin resistant pneumonia due to Staphylococcus aureus.  
All geocoded cases of ARI during the study period were summed for each 
census tract, and the tract was then identified demographically and 
geographically using the criteria described above. 
Selection of Liver and Kidney Cancers:  Cases of kidney cancer were 
ascertained from SCCCR using North American Association of Central Cancer 
Registries (NAACCR) ICD-O-3 codes.   Liver cancers included hepatic 
carcinomas and unspecified malignant hepatic tumors(ICD-O-3 codes C220 and 
C221), and kidney cancers included renal cell carcinomas and renal pelvis 
cancers (ICD-O-3 codes C649 and 659).  Again, the total number of geocoded 
liver and kidney cancers was summed up by each census tract and the tract was 
later geographically and demographically defined by using the methods above.    
Statistical Analyses:  Two tailed Student’s t-tests were used to compare the 
mean number of antibiotic prescriptions by census tract type.  Multivariate 
Poisson regression using empirical errors was used to assess the incidence risk 
ratios (IRRs) of ARI, liver, and kidney cancer by census tract type.  IRRs were 
used as estimators of relative risks ratios (RRs) in this study.  An offset variable, 
the population of the census tract from the 2000 U.S. Census, was used in these 
analyses to adjust for the different population sizes in each census tract.  A 
midpoint population was not able to be calculated and used as the census 
boundaries were redrawn for the 2010 U.S. Census, resulting in about 220 more 
census tracts in 2010 which had no equivalent in the 2000 Census.  Confounding 
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was assessed at the aggregate level by census tracts.  Only significant variables 
were included in each modeled outcome.  Data retrieval, management, and 
analyses were performed using SAS version 9.3 (SAS Institute Inc., Cary, NC) 
and P < 0.05 was used to determine statistical significance. 
Results 
Tertiles of antibiotic exposure by total number of prescriptions per census 
tract are reflected in Table 1.  Tertiles were used to give exposure level 
classifications of low, medium, and high.  Low exposure includes 293 census 
tracts which received a total of 0 to 2994 antibiotic prescriptions during the study 
period.  Medium exposure includes 290 tracts which received 2995 to 5297 total 
prescriptions, and 298 tracts received 5298 to 16,348 total prescriptions which 
were classified as having high exposure. 
Table 2 shows the overall prescribing patterns for census tracts in South Carolina 
by tract type.  The state is composed of almost 60% agricultural tracts and 40% 
industrial tracts and this is reflected in the total number of antibiotic prescriptions 
and the mean of prescriptions as well, as there are more antibiotic prescriptions 
in total and on average for agricultural than industrial tracts.  Coastal tracts make 
up only about a quarter of tracts while inland tracts make up the other three 
quarters, this is also the trend with total antibiotic prescriptions per tract type and 
mean prescriptions.  Fewer rural tracts are present in the state, and more than 
half are urban, with most total antibiotic prescriptions belonging to urban tracts.  
However, rural tracts have a higher mean number of prescriptions.  Most tracts 
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have a black population of 0 to 33%, fewer of the tracts have a black population 
between 34 and 66%, and fewer tracts have a black population between 67 to 
100% black.  The total number of prescriptions for each census tract type 
descends according to percentage types, as does mean prescriptions for each 
tract.  Student’s t-tests show that the means between the tract types are 
significantly different from each other. 
Relative risk ratios for antibiotic resistant infections by census tract type 
are displayed in Table 3.  Multivariate analyses resulted in only 2 significant 
covariates, those being number of antibiotic prescriptions and racial composition 
of census tracts.  Census tracts with 0 to 2994 prescriptions were the reference 
category, tracts with 2995 to 5297 prescriptions have an RR of 1.38 (1.10 – 
1.73), and tract with 5298 to 16348 prescriptions have an RR of 1.38 (1.10 – 
1.73).  These RRs appear identical due to rounding, but without rounding are 
1.3814 (1.1046 – 1.7275) and 1.3810 (1.1035 – 1.7283), respectively.  These 
RRs are significant with a p-value of 0.0040 and show that increased amounts of 
antibiotic prescriptions in these census tracts is a risk factor for ARI outcomes.  
The racial composition of census tracts was also a significant variable in this 
association, with a p-value of 0.0269.  Using census tracts with 0 to 33% black 
population as the referent level, tracts with 34 to 66% black population carried an 
RR of 1.09 (0.92 – 1.29), and tracts with 67 to 100% black population carried an 
RR of 1.49 (1.15 – 1.92).  Although the middle level of black population is not 
significant as the RR crosses the null value, the high level is significant, 
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suggesting that, when adjusted for total number of prescriptions, census tracts 
with high black populations have increased risks for an ARI outcome.   
Relative risk ratios for outcomes of liver cancer by census tract are shown 
in Table 4.  In this Poisson model, only the racial compositions of the census 
tracts were associated with liver cancer outcomes.  Increased black populations 
in census tracts carried increasing risks of liver cancer.  Living in a tract 
composed of 34 to 66% black population gave a risk of 1.43 (1.13 – 1.81) and 
living in a tract with 67 to 100% black population carried a risk of 2.15 (1.64 – 
2.80).  All other covariates were not statistically significant in this model, 
therefore, antibiotic exposure cannot be associated with liver cancer outcomes at 
the aggregate level. 
Modeling relative risk ratios for kidney cancer outcomes provided three 
significant covariates, number of antibiotic prescriptions per census tract, rural or 
urban designations of census tracts, and racial composition of the tract.  Data for 
these analyses is shown in Table 5 and all RRs are adjusted for these variables.  
A medium level of exposure to antibiotics yielded an RR of 1.20 (0.98 – 1.47) and 
a high level showed an RR of 1.51 (1.25 – 1.82).  Even though the middle level of 
exposure is insignificant, the high level of exposure carries an increased risk of 
kidney cancer outcomes.  Urban tracts showed a protective effect with an RR of 
0.86 (0.75 – 0.98).  Census tracts with greater than 33% black population 
showed increased risks of kidney cancer outcomes, when adjusted for other 
variables in this model.  Tracts composed of 34 to 66% black population gave a 
 73 
risk of 1.51 (1.31 – 1.74) and living in a tract with 67 to 100% black population 
carried a risk of kidney cancer of 2.04 (1.68 – 2.48). 
Discussion 
Looking at relative risk ratios from our study, our findings indicate 
significant differences in outcomes of antibiotic resistant infections, liver cancers, 
and kidney cancers by antibiotic exposure and census tract types.  Predictably, 
antibiotic exposure is associated with ARI outcomes.  However, higher 
percentages of black populations are also associated with an increase in ARI 
outcomes.  This effect is also seen when investigating liver cancer outcomes, but 
antibiotic exposure has no influence over liver cancer development.  Kidney 
cancer is associated with higher levels of antibiotic exposure, residing in a rural 
census tract, as well as with higher percentages of black populations in the tract. 
While it has been established that increased antibiotic use leads to the 
emergence of ARIs (12-15), this trend has not been investigated on a 
background of geographical and demographic differences.  However, this only 
seems natural as differential prescribing patterns in various region types have 
been uncovered in previous studies (16;17).  Our results show that the mean 
antibiotic prescriptions do vary based on geographical census tract type, as 
agricultural, inland, and rural areas receive more prescriptions, but this does not 
necessarily translate to increased risks for ARIs, or even liver or kidney cancers.  
From the RRs in this study, we have confirmed that antibiotic exposure is 
associated with ARI outcomes, but that geographical factors of the census tracts 
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do not influence this association.  However, demographics do influence this 
relationship as higher black populations show increased risk of ARI when 
adjusted for total number of prescriptions.    
Because of the hypotheses and studies by Setchell, Knekt, and Velicer, 
antibiotic usage in relationship to cancer is now also an avenue that requires 
examination.  Metabolic pathways allow the liver and kidneys the most exposure 
to antibiotics in the body, and therefore make these organs more at risk for 
developing toxicities and cancers.  This was seen in our analysis for kidney 
cancer, but not for liver cancer.   It may be that the kidneys’ continuous filtering 
and concentration of antibiotics in urine provides the kidney with more potent and 
constant exposure to antibiotic compounds in the body than the liver, leading to 
an increased risk in one organ but not the other.  In addition to antibiotic 
exposure and racial composition, rural and urban designations of the census 
tract affect kidney cancer outcomes.  Urban tracts carry a decreased risk for 
kidney cancer outcomes when adjusted for the other variables in the model.  In 
this case, it is also important to remember antibiotic exposures from 
environmental sources, for example rural census tracts are exposed to antibiotics 
in runoff from farms in which animals are treated with antibiotics, as well as 
airborne and waterborne exposure from orchards in which fruiting trees are 
sprayed with antibiotics.  This increased environmental exposure can also 
influence the relationship between kidney cancer and antibiotic usage.        
Furthermore, our findings suggest higher risks of ARIs, liver, and kidney 
cancer outcomes in tracts with higher percentages of black population, 
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specifically 67 to 100% of the population.  This may be due to socioeconomic 
statuses of these tracts, as areas such as these may be more rural and less 
likely to have routine access to health care, resulting in undesirable outcomes.  In 
addition, less routine access to healthcare may actually increase antibiotic 
exposure, as doctors would be more willing to prescribe antibiotics for a patient 
who cannot easily come back for a follow up appointment.  This difference may 
even indicate a biological or physiological phenomenon in which African 
Americans are unable to metabolize antibiotics as efficiently or completely as 
Caucasian populations, thus leading to these outcomes.  This type of dissimilarity 
between ethnicities is not unheard of, as it has been found that Asian and Native 
American populations do not possess all of the functional and active enzymes to 
metabolize alcohol as efficiently as Caucasians, and that this may lead to the 
undesirable outcome of alcoholism (31;32).  
Collectively, our results indicate that antibiotic usage is a risk factor for the 
development of antibiotic resistant bacterial infections and kidney cancers and 
that these risks can be magnified based on the types of census tracts in which 
people live.  Various characteristics of these tracts may lead to these increased 
risks, including environmental exposures to antibiotics, regular access to health 
care, and genetic dispositions of the populations in these tracts.  Our findings 
agree with the studies which show that antibiotics use is a major cause of 
resistance by bacteria and subsequent resistant infections (12-15), and in part, 
with studies by Knekt and Velicer, which show increased risks from antibiotics for 
breast cancer.  Here, we found that kidney cancer is associated with antibiotic 
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usage, but liver cancer is not.  Although the Knekt study briefly assessed these 
risks by urban, agricultural, and rural types, this study’s region types were more 
varied and inclusive, relying on geocoded data and defined criteria for region 
types.  The Velicer study did not address the effect of various region types.  Also, 
both the Knekt and Velicer study focused on breast cancer in women, while our 
methods focused on both men and women at risk for liver and kidney cancers.   
As an ecological study, there are limitations to these results.  Temporality 
cannot be accurately determined with this study, as there was no time line 
between antibiotic exposure and the disease outcome, so a proper cause and 
effect situation cannot be outlined.  As aggregate data and because our smallest 
unit of analysis is the census tract, risks at an individual level cannot be 
assessed.  At an individual level, the risks uncovered in this study may exist on a 
different scale or may not exist at all.  Additionally, confounding at an individual 
level cannot be assessed with this type of study and analysis.  
Strengths of this study include the linkage between SHP and Medicaid 
claims data with SCCCR data to ascertain and confirm the diagnoses of liver and 
kidney cancers in the population.  The claims data from SHP and Medicaid 
provided a relatively easy and inexpensive way to ascertain ARI diagnoses and 
the drug files allowed accurate antibiotic exposure data as well. This study was 
ideal for determining the rudimentary relationship between antibiotic usage and 
ARI, liver cancer, and kidney cancer outcomes in relation to census tract types, 
and offers hypotheses and conclusions for further exploration and investigation.  
From our study, it is important to now look at antibiotic usage not only as a whole 
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but against the background of varying geographical and demographic factors, 
and to realize that antibiotics do have a role in unwanted and potentially fatal 
outcomes.  Further targeted studies using case-control or cohort methodology 
would be the next step in identifying and describing an accurate relationship 
between antibiotic usage, negative outcomes, and prescribing patterns and 
geographical areas in South Carolina. 
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Table 4.1.   Tertiles of Antibiotic Exposure by Total Number of Antibiotic 
Prescriptions per Census Tract from January 2000 to December 
2009 
Exposure Level  
Classification 
Number of Total 
Antibiotic Prescriptions 
# of Census Tracts 
(n = 881) 
Low 0 – 2994 293 (33.3%) 
Medium 2995 – 5297 290 (33.0 %) 
High 5298 – 16348 298 (33.8%) 
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Table 4.2.  Antibiotic Prescriptions by Census Tracts in South Carolina 
from January 2000 to December 2009* 
Census Tract 
Characteristic 
 
# of 
Census 
Tracts 
(n = 881) 
# of Total 
Antibiotic 
Prescriptions 
(n = 3976569) 
Mean 
Antibiotic 
Prescriptions 
Per Tract 
t-test 
for 
Means 
Agricultural/Industrial     
Agricultural 523 
(59.8%) 
2710736 
(68.2%) 
5202.9 <0.000
1 
Industrial 351 
(40.2%) 
1265833 
(31.8%) 
3606.4 
Coastal/Inland     
Coastal 213 
(24.4%) 
855269 
(21.5%) 
4015.3 0.0011 
Inland 661 
(75.6%) 
3121300 
(78.5%) 
4736.4 
Rural/Urban     
Rural 322 
(36.8%) 
1634613 
(41.1%) 
5108.2 <0.000
1 
Urban 552 
(63.2%) 
2341956 
(58.9%) 
4242.7 
Racial Composition 
of Census Tracts 
    
0 to 33% Black 
Population 
517 
(59.2%) 
2475274 
(62.3%) 
4787.8  
<0.000
1 34 to 66% Black 
Population 
250 
(28.6%) 
1123890 
(28.3%) 
4495.6 
67 to 100% Black 
Population 
107 
(12.2%) 
377405 (9.5%) 3594.3 
* Missing data for agricultural/industrial, coastal/inland, rural/urban and racial 
composition of census tracts include 7 total missing (0.008%) tracts.  Variable 
stratum numbers may not equal total number of census tracts due to these 
missing data. 
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Table 4.3.  Relative Risk Ratios for Outcomes of Antibiotic Resistant 
Infections by Census Tract Type 
Census Tract 
Characteristic 
Relative Risk Ratio (95% 
CI†) 
P value for Trend 
Number of Antibiotic 
Prescriptions 
  
 
0 – 2994 Reference 
2995 – 5297 1.38 (1.10 – 1.73)‡ 0.0040 
5298 – 16348 1.38 (1.10 – 1.73)‡  
Racial Composition of 
Census Tracts 
  
 
0.0269 
 
0 to 33% Black Population Reference 
34 to 66% Black Population 1.09 (0.92 – 1.29) 
67 to 100% Black Population 1.49 (1.15 – 1.92) 
*RR estimates represent all significant variables in the multivariate model.  †CI = 
Confidence Interval.  ‡Due to rounding, these estimates seem identical, however 
the actual RR values for 2995 – 5297 and 5298 – 16348 prescriptions are 1.3814 
(1.1046 – 1.7275) and 1.3810 (1.1035 – 1.7283), respectively.     
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Table 4.4.  Relative Risk Ratios for Outcomes of Liver Cancer by Census 
Tract Type 
Census Tract Characteristic Relative Risk Ratio 
(95% CI†) 
P value for Trend 
Racial Compositions of 
Census Tracts 
  
 
<0.0001 
 
0 to 33% Black Population Reference 
34 to 66% Black Population 1.43 (1.13 – 1.81) 
67 to 100% Black Population 2.15 (1.64 – 2.80) 
*RR estimates represent all significant variables in the multivariate model.  †CI = 
Confidence Interval.    
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Table 4.5.  Relative Risk Ratios for Outcomes of Kidney Cancer by Census 
Tract Type 
Census Tract 
Characteristic 
Relative Risk Ratio (95% 
CI†) 
P value for Trend 
Number of Antibiotic 
Prescriptions 
  
0 – 2994 Reference  
2995 – 5297 1.20 (0.98 – 1.47) <0.0001 
5298 – 16348 1.51 (1.25 – 1.82)  
Rural/Urban   
0.0244 Rural Reference 
Urban 0.86 (0.75 – 0.98) 
Racial Composition of 
Census Tracts 
  
 
<0.0001 0 to 33% Black Population Reference 
34 to 66% Black Population 1.51 (1.31 – 1.74) 
67 to 100% Black 
Population 
2.04 (1.68 – 2.48) 
*RR estimates represent all significant variables in the multivariate model.  †CI = 
Confidence Interval.    
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CHAPTER 5 
Case-Control Study of Antibiotic Usage in Relation to Liver Cancer 
Outcomes in South Carolina2 
Introduction 
The overuse and misuse of antibiotics have caused various issues in 
today’s clinical settings.  Their unchecked use has led to the selection of drug 
resistant, in some cases, multiple drug resistant, bacterial strains and an 
increase in these types of infections.  In these cases, conventional antibiotics 
become useless as a treatment option (1-5).  In addition to causing an 
emergence of resistant bacterial infections, previous research has shown that the 
use of antibiotics can lead to the development of cancers.  The hypothesis that 
the use of antibiotics may increase the risk of cancer in humans was first 
suggested in 1981 by Setchell et al (6).  This study showed that antibiotics 
interfere with the ability of human intestinal microflora to metabolize plant 
estrogens into compounds which are protective against cancers.  Since then, 
studies by Knekt et al and Velicer et al have uncovered associations between 
antibiotic usage and cancer (7;8).  However, a lack of research currently exists 
examining the association between antibiotic use and cancer.  Furthermore, 
                                                           
2
 Thathiah, P., S.A. Adams, A. Merchant, R. Moran, K. Bennett, R. S. Norman.  
2014.  To be submitted to the Journal of the National Cancer Institute. 
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while both the Knekt and Velicer studies demonstrated that antibiotics may 
indeed be a risk for breast cancer, no other cancer type has been studied in 
relation to antibiotics.   
Physiologically, the liver is one of the body’s organs that experience the 
most exposure to drugs in the bloodstream, and therefore would presumably be 
a site with a substantial amount of risk for antibiotic-induced cancers.  The liver 
plays a vital role in the metabolism and processing of pharmaceuticals, including 
antibiotics, and is the most metabolically active tissue per unit of weight.  The 
liver is also the largest organ in the body, is perfused by blood containing drugs 
from the digestive tract, and houses the majority of drug metabolizing enzymes 
found in organs of the body, further cementing its vast role in drug metabolism.  
The liver accomplishes two phases of drug metabolism, and depending on the 
drug, both of these phases will be completed in sequence, or only one of the two 
phases will be performed.  Phase 1 reactions include oxidation, reduction, and 
hydrolysis of the drug which prepares it for the second phase to produce 
conjugation products.  Phase 2 conjugation reactions, which include 
glucoronidation, sulphation, and acetylation, increase the water solubility of the 
drug permitting its excretion in bile or urine.  Phase 2 reactions can also 
inactivate the drug or its active metabolites produced in phase 1 (4;9).  As a 
major player in drug metabolism, the liver is also prone to hepatotoxicities  as 
well as more serious drug induced liver injuries (DILI) (10), which may lead to 
more serious complications such as liver failure or the need for a liver transplant 
(11;12).  It is reasonable to suggest that cancers can result in the liver due to its 
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continued processing and exposure to excessive or unneeded antibiotics.  
Velicer et al suggest that use of antibiotics can lead to cancer in a number of 
ways.  Antibiotics affect the metabolism of the indigenous bacteria in the 
gastrointestinal tract, allowing for inefficient or incorrect processing of 
carcinogens, chemicals, and hormones.  Antibiotics can also interfere with 
immune and inflammatory responses, permitting an increase in production of 
inflammatory cytokines, prostaglandins, and enzymes (6;8;13;14).  These events 
can trigger somatic cells to proceed down a carcinogenic pathway and eventually 
produce fatal cancers. 
Moreover, many studies have pointed to various prescribing patterns for 
antibiotics based on geographic locations, and this in turn could affect cancer 
development in these areas if antibiotics prove to be a risk factor for cancer.  A 
global study found that urban areas, such as regions in Mexico and Kenya, have 
higher amounts of exposure to antibiotic when compared to more rural areas in 
these and other countries (15).  This geographical trend was also uncovered in a 
study in China (16).  Because of these disparities in prescribing patterns, it is 
feasible that cancer risk can vary in response to the levels of antibiotic exposure 
in these geographical regions. 
The studies by Knekt and Velicer have shown associations between 
treatment of women with antibiotics and breast cancer, suggesting that these 
chemotherapeutics may have a much more serious role in disease development.   
This study primarily addresses the use of antibiotics and their relationship to liver 
cancer outcomes in both males and females in South Carolina.  Additional 
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analyses including confounding and effect modification of demographic and 
geographic variables will be performed to describe this relationship more 
completely.       
Methods 
Data Sources:  This matched case-control study used existing demographic and 
pharmacy data and diagnostic codes from South Carolina Medicaid 
administrative claims and State Health Plan (SHP) claims data.  Specifically, 
pharmacy and drug files from Medicaid and SHP were used to ascertain 
antibiotic prescribing data.  The pharmacy and drug files provided information for 
all individuals in this study for the duration of the study period which included 
dates from January 1, 2000 to December 31, 2009.  They contained information 
such as days of therapy, drug strength, quantity provided, dispense date, 
National Drug Codes (NDC), and American Hospital Formulary System (AHFS) 
codes.  These appended datasets were integrated with liver cancer incidences 
from the South Carolina Central Cancer Registry (SCCCR), a division of the 
South Carolina Department of Health and Environmental Control (SCDHEC).  
Study participants represented both males and females aged 18 years or older.  
All participants were selected from patients enrolled in Medicaid or SHP 
continuously for at least 1 year before the diagnosis of liver cancer.  There were 
a total of 1620 participants in this study.  This study was approved by both the 
University of South Carolina and SCDHEC Institutional Review Boards. 
 93 
United States Census Bureau data from 2000 and the Department of Natural 
Resources(DNR) GAP data and Landcover codes 54 were used to determine 
geographical aspects of the state of South Carolina, including racial composition 
of census tracts, agricultural or industrial, coastal or inland, and rural or urban 
census tract designations.  Racial composition was determined by the 
percentage of black population within each tract categorized by tertiles, 0 to 33%, 
34 to 66%, and 67 to 100%.  Agricultural or industrial census tracts were 
determined by DNR Landcover Codes.  Industrial areas were defined as those 
with Landcover codes 22 and 23 (Urban development and Urban residential).  
Census tracts which were more than 50% developed were classified as 
industrial.  Census tracts with less than 50% development were classified as 
agricultural.  Coastal census tracts were defined within counties in the coastal 
zone, or the counties of Beaufort, Berkeley, Charleston, Colleton, Dorchester, 
Horry, Jasper, and Georgetown.  Census tracts in all other counties were defined 
as inland.  Using census data, census tracts which had greater than or equal to 
50% urban characteristics (urban areas with a population of 50,000 or more) 
were classified as urban, otherwise the tract was classified as rural.   
Antibiotic Usage:  Antibiotic usage was assessed by using Medicaid and SHP 
data.  This study was limited to antimicrobial agents effective against bacterial 
infections and excluded antiviral, antifungal, and antiparasitic agents, and were 
chosen by using American Hospital Formulary System (AHFS) codes.  These 
included:  081200 antibiotics (systemic), 081202 aminoglycosides, 081206 
cephalosporins, 081207 miscellaneous β-lactam antibiotics, 081208 
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chloramphenicol, 081212 macrolides, 081216 penicillins, 081218 quinolones, 
081220 sulfonamides (systemic), 081224 tetracyclines, 081228 antibacterials 
(miscellaneous), 081600 antimycobacterials, 081604 antituberculosis agents, 
081692 antimycobacterials (miscellaneous), 082200 quinolones, 082400 
sulfonamides (systemic), 082600 sulfones, 361600 brucellosis, 362800 
diphtheria, 367200 scarlet fever, and 368400 tuberculosis.  Furthermore, only 
antibiotics prescribed for oral use were included.  Topical and intravenous (IV) 
antibiotics were excluded.  IV antibiotics are usually given on an inpatient basis in 
hospitals while all oral antibiotics included in this study were outpatient 
prescriptions.   All prescriptions predated the diagnosis of liver cancer in the 
cases, which was used as the reference date.  For the controls, prescriptions 
predated their reference date, which was the last date of service in the claims 
data.   
Two measures of antibiotic usage were used, both having been adjusted (within 
the study design) for the time the participant was enrolled in Medicaid or SHP by 
matching on length of enrollment in the health plans.  The first measure was the 
total number of antibiotic prescriptions per participant during the study period.  
Total numbers of prescriptions by AHFS categories mentioned above were 
summed up over the study period by each participant and divided into quartiles 
for exposure levels.  The second predictor was the total days of antibiotic usage 
by each participant during the study period.  These values were calculated by 
summing up days of therapy variable for each prescription of each participant 
and then were divided into quartiles as well.  For days of use by antibiotic class, 
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the days of therapy variables for each prescription of each class was summed for 
each participant to generate the cumulative days of classes of antibiotic use.  For 
analysis by antibiotic class, the 6 most prescribed antibiotics in the dataset were 
used, representing 99.5% of all prescriptions by participants.  These were 
cephalosporins (31.9%), penicillins (22.4%), quinolones (19.8%), macrolides 
(13.0%), tetracyclines (6.6%), and miscellaneous antibacterials (5.9%).   
Selection of Liver Cancer Cases and Controls:  Cases of liver cancer were 
ascertained from SCCCR using North American Association of Central Cancer 
Registries (NAACCR) ICD-O-3 codes C220 and C221.   Liver cancers included 
hepatic carcinomas and unspecified malignant hepatic tumors.  Incidence density 
sampling was used as controls were randomly selected from Medicaid and SHP 
enrollees during the same years the cases were diagnosed.  Controls were 
frequency matched to cases at a ratio of 3:1 on age and length of enrollment in 
Medicaid or SHP, and type of insurance program, either Medicaid or SHP.  
Frequency matching ensured that the characteristics of the population of controls 
were similar to the characteristics of the cases.  Controls and cases with previous 
diagnoses of other cancers were restricted from the dataset, as were participants 
with multiple liver biopsies and diagnoses of liver cirrhosis, as these are usually 
associated with liver cancers.  This was done by using Current Procedural 
Terminology (CPT) and International Classification of Disease 9th revision codes 
(ICD-9).  CPT codes for biopsies included 4700, 47001, 47100, 37200, 36011, 
and 75970, ICD-9 codes for cirrhosis included 571.5, 571.2, and 571.  Due to 
privacy concerns from Medicaid and SHP, these groups were pooled and could 
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not be analyzed separately.  A total of 405 cases of liver cancer and 1215 
controls were identified.  All participants were given unique identification numbers 
to protect their anonymity.   
Statistical Analyses:  Conditional logistic regression was used to estimate the 
odds ratios of liver cancer associated with antibiotic use overall, by antibiotic 
class, sex, and population type.  Calculating odds ratios by class of antibiotic 
allowed for ascertainment of additional cancer risk by type of antibiotic, as one 
class may be associated more strongly than another with a cancer outcome.  
Furthermore, odds ratios were calculated separately by sex and population to 
examine any gender or geographic disparities that may have existed between the 
association between antibiotic usage and cancer outcomes.  The cancer 
outcome variable was categorical, either yes (1) or no (0), while the predictor 
variables of days of antibiotic use or number of prescriptions were divided into 
categories of exposure.  Data retrieval, management, and analyses were 
performed using SAS version 9.3 (SAS Institute Inc., Cary, NC) and P < 0.05 was 
used to determine statistical significance.  For effect modification, this was 
relaxed to P < 0.10 for interaction terms. 
Results 
As shown in Table 1, the exposure variables of total number of antibiotic 
prescriptions and total days of use were divided into quartiles.  Quartiles were 
chosen to reflect clinical practices, as the referent level corresponds to common 
antibiotic exposure in most individuals.  There were a total of 4374 antibiotic 
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prescriptions in the dataset and a total of 56245 days of use of antibiotics.  The 
dataset contains slightly more females than males, and this is true for controls as 
well.  However, there are more male cases of liver cancer than female cases.  
When looking at the racial composition of the census tracts in which the 
participants live, more than half of the controls and cases live in census tracts 
composed of 0 to 33 % African American population, with fewer living in a census 
tract composed of 34 to 66% black population, and even less living in a census 
tract with 67 to 100% black population.  The controls and cases have a similar 
break down for all categories of racial makeup for census tracts.  Most of the 
participants live in agricultural census tracts, inland census tracts, and urban 
census tracts.  The controls and cases have a comparable break down for 
demographic categories. 
The relationship between incident liver cancer and the total number of 
prescriptions, the first predictor variable, adjusted for sex, is displayed in Table 2.   
The reference level was between 0 to 4 prescriptions during the study period, 
and the results show odds ratios of 1.07 (0.77 – 1.49) for 5 to 63 total 
prescriptions, 1.03 (0.72 – 1.46) for 64 to 204 prescriptions, and 1.39 (0.98 – 
1.98) for 205 to 4374 prescriptions.  These ORs are not statistically significant as 
all 95% confidence intervals cross 1, suggesting that no risk exists between the 
use of antibiotics and liver cancer outcomes.  No other variables, besides sex, 
were shown to be confounders between this relationship.  This analysis was also 
performed with data divided into quintiles and showed similar results. 
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Effect modification by all demographic variables was investigated in these 
analyses.  Coastal and inland census tracts were investigated as effect modifiers 
displayed in Table 3.  While the p-value was 0.1020 for the interaction, none of 
the ORs were significant in that all of the 95% confidence intervals crossed 1.  
However, it is interesting to note the pattern of the ORs as the ORs for the lower 
and highest level of exposure for both coastal, 1.39 (0.40 0 4.78) and 2.35 (0.67 
– 8.31), and inland census tracts, 1.02 (0.68 – 1.55) and 1.55 (0.99 – 2.44) show 
an increase in risk, but the middle levels of exposure, 0.59 (0.16 – 2.23) for 
coastal and 0.99 (0.63 – 1.55) for inland, show a protective effect.  Sex, 
agricultural or industrial census tracts, and urban or rural census tracts were not 
shown to be effect modifiers between total number of antibiotic prescriptions and 
liver cancer development. 
The relationship between the second predictor variable, days of use of 
antibiotics, and liver cancer is shown in Table 4.  While sex was a confounder for 
the association between incident liver cancer and total number of antibiotic 
prescriptions, it was shown to be an effect modifier in the association between 
liver cancer and total days of antibiotic use.   Table 4 shows a p-value of 0.0082 
for sex as an effect modifier, and has the stratified ORs for this relationship.  
When comparing the ORs for each strata across sex, 27 to 448 days of use gives 
an OR of 1.34 (0.77 – 2.32) for females and 0.71 (0.41 – 1.21) for males, 449 to 
1590 days gives an OR of 0.69 (0.37 – 1.28) for females and 1.36 (0.80 – 2.31) 
for males, and 1591 to 56246 days of use gives an OR of 1.75 (0.97 – 3.17) for 
females and 1.03 (0.60 – 1.767) for males.  The ORs for each strata of female 
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and male are dissimilar from each other, but within each sex, they also cross the 
null value of 1.  While none of these OR’s are statistically significant, these 
patterns do show some effect modification by sex, resulting in differential risk 
estimates for each group.  At the lower exposure level, women have an 
increased risk of cancer while men seem to be protected from cancer outcomes. 
The middle level of exposure flips this trend, and men have an increased 
risk but women are protected.  For the highest exposure level, both sexes are at 
risk, but females carry a higher risk than males.  While the patterns of ORs are 
interesting, an association between antibiotic usage and liver cancer can not be 
confirmed.  Yet, in spite of the lack of statistical significance for all stratified ORs, 
the significant p-value for the trend suggests that sex is an effect modifier 
between antibiotic usage by days and liver cancer outcomes. 
All other demographic variables were investigated as potential effect 
modifiers for this relationship.  Table 5 and 6 show the stratified results from 
these analyses.  With a p-value of 0.0763, coastal or inland census tracts 
suggest effect modification between antibiotic usage by days and liver cancer, 
however none of the ORs are significant.  For 27 to 448 days of antibiotic use, 
the ORs are 1.28 (0.41 – 4.01) for coastal and 1.01 (0.66 – 1.54) for inland, 1.20 
(0.36 – 4.05) for coastal and 1.00 (0.64 – 1.53) for inland for 449 to 1590 days of 
use, and 1.63 (1.46 – 5.72) for coastal and 1.47 (0.95 – 2.27) for inland for 1591 
to 56246 days of use.  While these ORs are similar between the strata, indicating 
similar levels of risk, the p-value makes the observation that coastal or inland 
census tracts modify the association of days of usage and liver cancer plausible.  
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A strong effect modifier for this association may be the agricultural or industrial 
classification of the census tract, shown in Table 6.  With a p-value of 0.0340 for 
the trend, it is statistically significant at less than 0.05.  The ORs for 27 to 448 
days of use are 1.50 (0.92 – 2.44) for agricultural and 0.65 (0.30 – 1.42) for 
industrial, for 449 to 1590 days of use 0.80 (0.48 – 1.34) for agricultural and 1.45 
(0.68 – 3.12) for industrial, and for 1591 to 56246 days of use, the OR for 
agricultural is 1.60 (0.98 – 2.64) and 0.78 (0.34 – 1.76) for industrial.  These ORs 
show differential risks of cancer for each stratum in agricultural and industrial 
census tracts, but none of these ORs are significant statistically.  All other 
covariates were not found to be effect modifiers or confounders. 
Analyses to discover the additional risk posed by specific classes of 
antibiotics were carried out as well.  Table 7 illustrates the association between 
liver cancer outcomes and total number of prescriptions by antibiotic class.  
These antibiotics were the 6 most common classes prescribed in the dataset and 
composed 99.5% of all prescriptions.  The reference levels were those 
participants who had 0 prescriptions of the antibiotic in question, but they could 
have had prescriptions of other antibiotics.  This gives the additional risk of the 
antibiotic class and is in accordance with current prescribing practices, as 
patients are usually exposed to at least one antibiotic in any given year.  
Because of the small numbers of those who were exposed to these antibiotic 
classes, there is a dichotomous distribution among these exposure groups.  ORs 
for use of cephalosporins, penicillins, quinolones, macrolides, and miscellaneous 
antibacterials were 1.02 (0.68 – 1.53), 1.03 (0.70 – 1.52), 1.27 (0.86 – 1.85), 1.01 
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(0.68 – 1.50), and 1.72 (0.88 – 3.34), respectively.  The use of tetracyclines had 
an OR of 0.89 (0.52 – 1.54).  All of the 95% confidence intervals for these 
findings cross 1, and therefore are not significant, suggesting that the use of 
individual classes of antibiotics have no effect on liver cancer outcomes.    
Discussion 
Our findings showed that antibiotic usage is not a risk factor for the 
development of liver cancer, as none of the ORs were statistically significant.  
The relationship between exposure and outcome, however, was confounded by 
sex when total number of prescriptions was used as the exposure variable or 
was effect modified when total days of use of antibiotics was used as the 
exposure variable during analysis.  Specific classes of antibiotics were also 
investigated as potential cancer risks, both by total numbers of prescriptions and 
total days of use.  Again, these results were not statistically significant and 
cannot be established as risks for liver cancer outcomes. 
Several differences in the analyses were noted when using each predictor 
variable.  When using total number of prescriptions as the exposure, sex was a 
positive confounder, resulting in a shift away from the null from the crude OR 
estimates.  Sex itself is already a documented risk factor for liver cancer, as men 
are at least 2.4 times more likely than women to develop these cancers (17).  
However, when using days of antibiotic use, sex was an effect modifier, resulting 
in different risk estimates for males and females at each level of exposure.  Even 
though sex was also a positive confounder in these analyses, the significance of 
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the interaction term points towards effect modification as a major player in this 
association.  Effect modification by sex for cancer outcomes have been 
described previously in the context of alcohol consumption and renal cell 
carcinomas, resulting in lower risks of cancer with increased alcohol consumption 
in women, due in part to differences in alcohol and estrogen metabolism in 
women (23).  In this study, our two predictor variables are highly correlated, but 
the days of use variable is more subjective.  For example, men may follow the 
allotted course of antibiotics and thus receive more exposure than females who 
may cut the course of treatment short, or vice versa.  This could result in the 
different risk estimates for each group as the exposure levels are changing.  
Total number of prescriptions does not rely on the behaviors of patients, but is 
reflected as a doctor prescribed constant variable. 
Another difference between the analyses using these two predictors is 
effect modification by demographic variables.  For total prescriptions, only a 
coastal or inland census tract was a potential effect modifier, but for days of 
antibiotic use, in addition to sex, coastal or inland census tracts and agricultural 
or industrial census tracts were effect modifiers.  Generally, living in a coastal 
and agricultural census tract provided greater risk.  This could be due to the 
greater environmental exposure to antibiotics in these regions, for example from 
waste water runoff in coastal tracts and farming and veterinary use in agricultural 
tracts (18-22).  Further research needs to be conducted to take into account this 
environmental exposure as a significant risk for the development of cancer 
outcomes.   
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Analyses by total prescriptions by classes of antibiotics did not result in 
increased risks of liver cancer from cephalosporins, penicillins, quinolones, 
macrolides, miscellaneous antibacterials, and tetracyclines.  Further analysis 
using days of use was also carried out and led to identical results to those in 
Table 7.  Due to the insufficient numbers in each level, we were unable to 
properly assess risks across varying exposure levels.   In the future, with a larger 
dataset, more levels of exposure can be teased out, therefore leading to a better 
resolution for detecting these associations by each predictor.        
Our findings agree with those from the Knekt et al study.  While we 
detected increased risks from antibiotic usage for liver cancer, our findings were 
also not always statistically significant, as with the Knekt findings.  However, the 
Knekt study was a cohort study which only investigated antibiotic usage in 
response to urinary tract infections as a risk for cancer, while our case-control 
study did not have the restriction of antibiotics prescribed for certain types of 
infections.  By doing so, we studied antibiotic usage as the sole risk factor and 
not the original infections.  While they did find increased risk associated with 
antibiotic usage and breast cancer, this was displayed in premenopausal women 
who received antibiotics for a urinary tract infection, our study indicates that this 
risk is present in men and women of various ages who were prescribed 
antibiotics for varying conditions. While they did uncover a weak protective 
association between agricultural and industrial areas compared to urban centers, 
this study found that coastal and agricultural regions bore greater risks for liver 
cancer with antibiotic use as an exposure.  
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However, the conclusions from our study did not agree with the results 
from the Velicer et al study.  The Velicer study noted significant risks from 
antibiotic usage for liver cancer, but our finding were not significant.   While the 
study by Velicer detected risks posed by all major antibiotics classes in their 
dataset for total prescriptions and days of use, we did not find these same risks 
for any of the most common antibiotics in our dataset.  Our study differs from the 
Velicer study as well because their study included only women, as it was 
primarily a breast cancer study.  Also, our study only included incident cases of 
liver cancer, we did not study fatal cases of liver cancer.  We further investigated 
confounding and interaction by demographic and geographical variables, and 
uncovered these effects in our study. 
The foremost limitation in this study is that even though antibiotics were 
prescribed to participants, there is no way of knowing if the prescriptions were 
actually filled or administered correctly, for example at the right times and for the 
full course of treatment.  Inpatient use of antibiotics was not factored into this 
study.  Furthermore, this analysis did not take into account the timing between 
multiple antibiotic courses.  Additional studies need to be performed to examine if 
risk increases from shorter time intervals between antibiotic courses versus 
longer intervals.  In addition, there was no data about other risk factors for liver 
cancer or hepatic carcinomas, such as genetic disposition or smoking and 
alcohol consumption.  Residual confounding by socioeconomic status may also 
be influencing these results, but was not directly addressed in these analyses.  
Furthermore, due to the small sample size of this study, it was difficult to detect 
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an association between exposure and outcome.  Repeated analyses with a 
larger sample size may yield more consistent findings with those of Velicer. 
The strengths of this study include the unique linkage between Medicaid 
and SHP data administrative claims to data from SCCCR.  This allowed for the 
accurate determination of pharmacy records for participants and the lack of recall 
bias as no interviews had to be performed to obtain exposure status.  Data were 
complete for antibiotic prescriptions, including drug names, National Drug Codes, 
American Hospital Formulary System information, days supplied, and number of 
prescriptions for each class of antibiotic.  Also, by linking to a disease registry, 
we had a defined cohort from which cases could be chosen, along with the 
demographic data and detailed cancer information which comes from SCCCR.  
We did not include individuals who switched from one health plan to another, as 
a participant had to be enrolled continuously in either plan to be eligible for this 
study.  This avoided missing data from periods of time with no insurance 
coverage or before switching to a different plan.  As a whole, this study 
addresses risks for liver cancer development in relation to antibiotic usage in a 
wider population, both men and women, in various regions in the state of South 
Carolina, allowing for greater generalizability of this study’s findings.  Drug 
metabolism pathways were also considered in this study, as the liver is the main 
organ in the body responsible for metabolizing, processing and breaking down of 
antibiotics.  Therefore, this organ should be closely monitored and studied as a 
site for cancer development in light of use, overuse, and misuse of antibiotics.  
As exposure levels increase, this study aimed to divide the data into appropriate 
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sample sizes for each category, providing more powerful results.  The fact that 
cumulative exposure results could be repeated by dividing the data into quintiles, 
as well as quartiles, lends credibility to these findings. 
To conclude, we did not uncover evidence to suggest that the use of oral 
antibiotics is associated with  the development of liver cancer.  These results 
suggest that demographic and geographical variables may influence this 
relationship, but further analyses with a larger sample size are needed to 
accurately describe this association.  In addition, specific classes of antibiotics 
were not shown to be more associated with cancer outcomes than others.  
Clinically, these findings are not pertinent.  Yet in light of findings from previous 
studies and the toxic nature of antibiotics, safer prescribing of antibiotics as well 
as reducing the exposure to antibiotics in the generally healthy adult population 
seems prudent.  While this family of drugs has proven its effectiveness and 
advantages over the past decades, recent medicine has been negatively affected 
by their use, including the emergence of resistant bacterial infections, and now 
as a potential risk factor for cancers.      
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Table 5.1.  Descriptive Characteristics of Controls and Liver Cancer Cases* 
Characteristic All Participants 
(n = 1620) 
Controls 
(n = 1215) 
Cases 
(n = 405) 
Quartiles of Antibiotic Exposure by Total Number of Prescriptions 
0 – 4 398 (24.6%) 296 (24.4%) 102 
(25.2%) 
5 – 63 404 (24.9%) 306 (25.2%) 98 (24.2%) 
64 – 204 415 (25.6%) 323 (26.6%) 92 (22.7%) 
205 – 4374 403 (24.9%) 290 (23.9%) 113 
(28.0%) 
Quartiles of Antibiotic Exposure by Total Days of Use 
0 – 26 398 (24.6%) 295 (24.3%) 103 
(25.4%) 
27 – 448 411 (25.4%) 313 (25.8%) 98 (24.2%) 
449 – 1590 407 (25.1%) 317 (26.1%) 90 (22.2%) 
1591 - 56246 404 (24.9%) 290 (23.9%) 114 
(28.2%) 
Sex    
Female 945 (58.3%) 794 (65.4%) 151 
(37.3%) 
Male 675 (41.7%) 421 (34.6%) 254 
(62.7%) 
Racial Composition of Census Tract 
0 – 33% Black 880 (54.3%) 659 (54.2%) 221 
(54.6%) 
34 – 66% Black 496 (30.6%) 372 (30.6%) 124 
(30.6%) 
67 – 100% Black 244 (15.1%) 184 (15.1%) 60 (14.8%) 
Agricultural/Industrial Census Tract 
Agricultural 1008 (65.2%) 757 (66.1%) 251 
(62.7%) 
Industrial 538 (34.8%) 389 (33.9%) 149 
(37.3%) 
Coastal/Inland Census Tract 
Coastal 361 (23.4%) 254 (22.2%) 107 
(26.8%) 
Inland 1185 (76.6%) 892 (77.8%) 293 
(73.2%) 
Urban/Rural Census Tract 
Rural 613 (39.6%) 466 (40.7%) 147 
(36.7%) 
Urban 933 (60.4%) 680 (59.3%) 253 
(63.3%) 
 *Data were complete for exposures and sex and racial composition of census 
tracts.  Missing data for all other variables include 74 (4.6%) total missing, 69 
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controls (5.7%) and 5 cases (1.2%).  Variable stratum numbers may not equal 
total number of cases or controls due to these missing data. 
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Table 5.2.  Relationship Between Incident Liver Cancer and Total Number of 
Prescriptions 
Number of 
Prescriptions 
Controls 
(n = 1215) 
Cases 
(n = 405) 
OR (95% CI)* P value 
for Trend 
0 – 4 296 (24.4%) 102 (25.2%) Reference  
 
0.2280 
5 – 63 306 (25.2%) 98 (24.2%) 1.07 (0.77 – 
1.49) 
64 – 204 323 (26.6%) 92 (22.7%) 1.03 (0.72 – 
1.46) 
205 - 4374  290 (23.9%) 113 (27.9%) 1.39 (0.98 – 
1.98) 
*Adjusted for sex.  Abbreviations:  OR = odds ratio; CI = confidence interval. 
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Table 5.3.  Effect Modification of Coastal or Inland Census Tract on Incident 
Liver Cancer and Total Number of Prescriptions* 
Number of 
Prescriptions 
Controls 
(n = 1215) 
Cases 
(n = 405) 
OR (95% CI) P value for 
Interaction 
Coastal     
 
 
 
0.1020 
0 – 4 72 (6.3%) 27 (6.8%) Reference 
5 – 63 57 (5.0%) 28 (7.0%) 1.39 (0.40 – 
4.78) 
64 – 204 71 (6.2%) 26 (6.5%) 0.59 (0.16 – 
2.23) 
205 - 4374  54 (4.7%) 26 (6.5%) 2.35 (0.67 – 
8.31) 
Inland    
0 – 4 214 (18.7%) 74 (18.5%) Reference 
5 – 63 231 (20.2%) 70 (17.5%) 1.02 (0.68 – 
1.55) 
64 – 204 232 (20.2%) 64 (16.0%) 0.99 (0.63 – 
1.55) 
205 - 4374  215 (18.8%) 85 (21.3%) 1.55 (0.99 – 
2.44) 
*Missing data include 69 controls (5.7%) and 5 cases (1.2%).  Variable stratum 
numbers may not equal total number of cases or controls due to these missing 
data.  Abbreviations:  OR = odds ratio; CI = confidence interval.   
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Table 5.4.  Effect Modification of Sex on Incident Liver Cancer and Total 
Days of Antibiotic Use 
Number of 
Days of 
Antibiotic 
Use 
Controls 
(n = 1215) 
Cases 
(n = 405) 
OR (95% CI) P value for 
Interaction 
Female     
 
 
 
0.0082 
0 – 26 168 (13.8%) 30 (7.4%) Reference 
27 – 448 211 (17.4%) 48 (11.9%) 1.34 (0.77 – 
2.32) 
449 – 1590 229 (18.9%) 26 (6.4%) 0.69 (0.37 – 
1.28) 
1591 - 56246  186 (15.3%) 47 (11.6%) 1.75 (0.97 – 
3.17) 
Male    
0 – 26 127 (10.5%) 73 (18.0%) Reference 
27 – 448 102 (8.4%) 50 (12.4%) 0.71 (0.41 – 
1.21) 
449 – 1590 88 (7.2%) 64 (15.8%) 1.36 (0.80 – 
2.31) 
1591 - 56246  104 (8.6%) 67 (16.5%) 1.03 (0.60 – 
1.77) 
Abbreviations:  OR = odds ratio; CI = confidence interval.   
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Table 5.5.  Effect Modification of Coastal or Inland Census Tract on Incident 
Liver Cancer and Total Days of Antibiotic Use* 
Number of 
Days of 
Antibiotic 
Use 
Controls 
(n = 1215) 
Cases 
(n = 405) 
OR (95% CI) P value for 
Interaction 
Coastal     
 
 
 
0.0763 
0 – 26 70 (6.1%) 27 (6.8%) Reference 
27 – 448 61 (5.3%) 30 (7.5%) 1.28 (0.41 – 
4.01) 
449 – 1590 65 (5.7%) 26 (6.5%) 1.20 (0.36 – 
4.05) 
1591 - 56246  58 (5.1%) 24 (6.0%) 1.63 (0.46 – 
5.72) 
Inland    
0 – 26 215 (18.7%) 75 (18.8%) Reference 
27 – 448 230 (20.1%) 67 (16.8%) 1.01 (0.66– 
1.54) 
449 – 1590 234 (20.4%) 63 (15.8%) 1.00 (0.64 – 
1.53) 
1591 - 56246  213 (18.6%) 88 (22.0%) 1.47 (0.95 – 
2.27) 
*Missing data include 69 controls (5.7%) and 5 cases (1.2%).  Variable stratum 
numbers may not equal total number of cases or controls due to these missing 
data.  Abbreviations:  OR = odds ratio; CI = confidence interval.   
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Table 5.6.  Effect Modification of Agricultural or Industrial Census Tract on 
Incident Liver Cancer and Total Days of Antibiotic Use* 
Number of 
Days of 
Antibiotic 
Use 
Controls 
(n = 1215) 
Cases 
(n = 405) 
OR (95% CI) P value for 
Interaction 
Agricultural     
 
 
 
0.0340 
0 – 26 174 (15.2%) 60 (15.0%) Reference 
27 – 448 194 (16.9%) 68 (17.0%) 1.50 (0.92 – 
2.44) 
449 – 1590 211 (18.4%) 47 (11.8%) 0.80 (0.48 – 
1.34) 
1591 - 56246  178 (15.5%) 76 (19.0%) 1.60 (0.98 – 
2.64) 
Industrial    
0 – 26 111 (9.7%) 42 (10.5%) Reference 
27 – 448 97 (8.5%) 29 (7.3%) 0.65 (0.30 – 
1.42) 
449 – 1590 88 (7.7%) 42 (10.5%) 1.45 (0.68 – 
3.11) 
1591 - 56246  93 (8.1%) 36 (9.0%) 0.78 (0.34 – 
1.76) 
*Missing data include 69 controls (5.7%) and 5 cases (1.2%).  Variable stratum 
numbers may not equal total number of cases or controls due to these missing 
data.  Abbreviations:  OR = odds ratio; CI = confidence interval.  
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Table 5.7.  Relationship between Incident Liver Cancer and Total Number of 
Prescriptions by Antibiotic Class* 
Number of 
PrescriptionsE 
Controls 
(n = 3705) 
Cases 
(n = 1235) 
OR (95% CI) P value for 
Trend 
Cephalosporins     
0.9097 0 1074 (88.4%) 357 (88.2%) Reference 
1 – 480 141 (11.6%) 48 (11.8%) 1.02 (0.68 – 
1.53) 
Penicillins     
0.8664 0 1031 (84.9%) 343 (84.7%) Reference 
1 – 1001 184 (15.1%) 62 (15.3%) 1.03 (0.70 – 
1.52) 
Quinolones     
0.2077 0 1036 (85.3%) 336 (83.0%) Reference 
1 – 837 179 (14.7%) 69 (17.0%) 1.27 (0.86 – 
1.85) 
Macrolides     
0.9439 0 1057 (87.0%) 352 (86.9%) Reference 
1 – 650 158 (13.0%) 53 (13.1%) 1.01 (0.68 – 
1.50) 
Tetracyclines     
0.6819 0 1148 (94.5%) 385 (95.1%) Reference 
1 – 799 67 (5.5%) 20 (4.9%) 0.89 (0.52 – 
1.54) 
Miscellaneous Antibacterials  
 
0.1113 
0 1188 (97.8%) 390 (96.3%) Reference 
1 – 850 27 (2.2%) 15 (3.7%) 1.72 (0.88 – 
3.34) 
 *The reference group for these analyses includes cases and controls with zero 
prescriptions of the specific antibiotic class in question during the regression.  
However, these participants may have had prescriptions for one of the other 
antibiotic classes in these analyses or an antibiotic which was not represented 
above.  ‡Representing the 6 most prescribed antibiotic classes in the dataset 
(99.5% of all antibiotic prescriptions).  Abbreviations:  OR = odds ratio; CI = 
confidence interval. 
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CHAPTER 6 
Case-Control Study of Antibiotic Usage in Relation to Kidney Cancer 
Outcomes in South Carolina3 
Introduction 
Antibiotics have been hailed as one of the most beneficial discoveries in 
medicine and public health, however the cytotoxic effects of these drugs may 
play a role in cancer development.  A paucity of literature currently exists 
examining the association between antibiotic usage and cancer.  The hypothesis 
that the use of antibiotics may increase the risk of cancer in humans was first 
suggested in 1981 by Setchell et al (1).  This study determined antibiotics have a 
direct negative impact on human intestinal flora when metabolizing plant 
estrogens into compounds which are protective against cancer.  To date, only 
two studies have been published investigating this link, and both studies focused 
on antibiotic utilization and breast cancer (2; 3).  While these studies by Knekt et 
al and Velicer et al demonstrated that antibiotics may indeed be a risk for breast 
cancer, no other cancer type has been evaluated in relation to antibiotic usage.  
Furthermore, these studies focused mainly on women and only the Knekt study 
investigated basic geographic regions as a covariate.
                                                           
3
 Thathiah, P., S.A. Adams, A. Merchant, R. Moran, K. Bennett, R. S. Norman.  
2014.  To be submitted to Cancer Epidemiology,Biomarkers & Prevention. 
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Antibiotics are very powerful drugs and have many known adverse side 
effects.  These range from relatively mild, even asymptomatic, reactions to 
serious and life threatening conditions.  Some of the most serious include 
toxicities of the body’s organs or organ systems resulting in use of antibiotics 
(9;10).  Among the organs within the body, the kidneys play a leading role in 
metabolizing and excreting chemotherapeutics, and are therefore prone to 
developing toxicities (7;11-14).  Although toxicities can be induced by antibiotics, 
it is feasible that even more serious complications, such as cancers, can arise.  
Velicer et al suggest that antibiotics increase the risk of cancer in a number of 
ways.  First, antibiotics affect the metabolism of the microflora in the 
gastrointestinal tract, allowing for inefficient or incorrect processing of 
carcinogens, chemicals, and hormones.  Antibiotics can also interfere with 
immune and inflammatory responses, permitting an increase in production of 
inflammatory cytokines, prostaglandins, and enzymes (1;3;15;16).  These events 
can trigger somatic cells to proceed down a carcinogenic pathway and eventually 
produce fatal cancers. 
Physiologically, the kidneys experience the largest amount of exposure, 
except for the liver, to drugs in the bloodstream, and therefore would presumably 
carry a substantial amount of risk for antibiotic induced cancers.  The kidneys not 
only mediate drug excretion but also play a role in the metabolism of drugs.  
Studies have shown that the kidneys carry out certain metabolic functions at a 
faster rate than the liver (4-6), and its metabolic repertoire has thus expanded in 
the past few decades.  The kidneys receive a large amount of blood during 
 121 
circulation, about 25% of resting cardiac output (7) and are therefore routinely 
and directly exposed to drugs and compounds in the bloodstream (6).  
Biochemical reactions in the kidneys, which include the same types of phase 1 
and phase 2 reactions that occur in the liver, are capable of activating or 
inactivating drug compounds and may produce metabolic byproducts which are 
toxic to the organ.  Blood flow through the kidneys, the pH of urine, and urine 
filtration pathways provide increased concentrations of drugs in various sections 
of the kidney, which may subsequently lead to damage of the organ (8). 
Moreover, many studies have pointed to various prescribing patterns for 
antibiotics based on geographic locations, and this in turn could affect cancer 
development in these areas if antibiotics prove to a risk factor for cancer.  A 
global study found that urban areas, such as regions in Mexico and Kenya, have 
higher amounts of exposure to antibiotic when compared to more rural areas in 
these and other countries (17).  This geographical trend was also uncovered in a 
study in China (18).  Because of these disparities in prescribing patterns, it is 
feasible that cancer risk can vary in response to the levels of antibiotic exposure 
in these geographical regions. 
The studies by Knekt and Velicer have shown associations between 
treatment of women with antibiotics and breast cancer, suggesting that these 
chemotherapeutics may have a much more serious role in disease development.   
This study aims to fill the gaps in the research regarding antibiotic usage and its 
relationship to kidney cancer outcomes in both males and females.  Confounding 
and effect modification by demographic and geographic variables will be further 
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investigated to describe the relationship between development of kidney cancer 
and antibiotic usage.       
Methods 
Data Sources:  This matched case-control study used existing demographic and 
pharmacy data and diagnostic codes from South Carolina Medicaid 
administrative claims and State Health Plan (SHP) claims data.  SHP is a 
comprehensive health plan offered to all government employees in the state of 
South Carolina.  Specifically, pharmacy and drug files from Medicaid and SHP 
were used to ascertain antibiotic prescribing data.  The pharmacy and drug files 
provided information for all individuals in this study for the duration of the study 
period which included dates from January 1, 2000 to December 31, 2009.  They 
contained information such as days of therapy, drug strength, quantity provided, 
dispense date, National Drug Codes (NDC), and American Hospital Formulary 
System (AHFS) codes.  These appended datasets were integrated with kidney 
cancer incidences from the South Carolina Central Cancer Registry (SCCCR), a 
division of the South Carolina Department of Health and Environmental Control 
(SCDHEC).     Study participants represented both males and females aged 18 
years or older.  All participants were selected from patients enrolled in Medicaid 
or SHP continuously for at least 1 year before the diagnosis of kidney cancer.  
There were a total of 4940 participants in this study.  This study was approved by 
both the University of South Carolina and SCDHEC Institutional Review Boards. 
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United States Census Bureau data from 2000 and the Department of Natural 
Resources(DNR) GAP data, including corresponding 54 class land cover codes, 
were used to determine geographical aspects of the state of South Carolina.  
These included racial composition of census tracts, agricultural or industrial, 
coastal or inland, and rural or urban census tract designations.  Racial 
composition was determined by the percentage of black population within each 
tract categorized by tertiles, 0 to 33%, 34 to 66%, and 67 to 100%.  Agricultural 
or industrial census tracts were determined by DNR Landcover Codes.  Industrial 
areas were defined as those with Landcover codes 22 and 23 (Urban 
development and Urban residential).  Census tracts which were more than 50% 
developed were classified as industrial.  Census tracts with less than 50% 
development were classified as agricultural.  Coastal census tracts were defined 
within counties in the coastal zone, or the counties of Beaufort, Berkeley, 
Charleston, Colleton, Dorchester, Horry, Jasper, and Georgetown.  Census tracts 
in all other counties were defined as inland.  Using census data, census tracts 
which had greater than or equal to 50% urban characteristics (urban areas with a 
population of 50,000 or more) were classified as urban, otherwise the tract was 
classified as rural.   
Antibiotic Usage:  Antibiotic usage was assessed by using Medicaid and SHP 
data.  This study was limited to antimicrobial agents effective against bacterial 
infections and excluded antiviral, antifungal, and antiparasitic agents, and were 
chosen by using AHFS codes.   Furthermore, only antibiotics prescribed for oral 
use were included.  Topical and intravenous (IV) antibiotics were excluded.  IV 
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antibiotics are usually given on an inpatient basis in hospitals while all oral 
antibiotics included in this study were outpatient prescriptions.   All prescriptions 
predated the diagnosis of kidney cancer in the cases, which was used as the 
reference date.  For the controls, prescriptions predated their reference date, 
which was the last date of service in the claims data.   
Two measures of antibiotic usage were used, both having been adjusted for the 
time the participant was enrolled in Medicaid or SHP by matching on length of 
enrollment in the health plans.  The first measure was the total number of 
antibiotic prescriptions per participant during the study period.  Total number of 
prescription categories were summed up over the study period by each 
participant and divided into tertiles for exposure levels.  The second predictor 
was the total days of antibiotic usage by each participant during the study period.  
These values were calculated by summing up days of therapy variable for each 
participant for each prescription to generate the cumulative days of antibiotic use, 
and were also divided into tertiles.  For analysis by antibiotic class, the 6 most 
prescribed antibiotics in the dataset were used, representing 81.3% of all 
prescriptions by participants.  These were aminoglycosides (20.7%), 
cephalosporins (17.0%), penicillins (14.4%), quinolones (19.1%) tetracyclines 
(5.4%), and sulfonamides (4.9%).  These were divided into levels of exposure by 
natural breaks in the data, but also allowing for an appropriate sample size in 
each level.   
Selection of Kidney Cancer Cases and Controls:  Cases of kidney cancer were 
ascertained from SCCCR using North American Association of Central Cancer 
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Registries (NAACCR) ICD-O-3 codes.   Kidney cancers included renal cell 
carcinomas and renal pelvic cancers.  Incidence density sampling was used as 
controls were randomly selected from Medicaid and SHP enrollees during the 
same years the cases were diagnosed.  Controls were frequency matched to 
cases at a ratio of 3:1 on age, length of enrollment in Medicaid or SHP, and type 
of insurance program, as the controls either used Medicaid or SHP, but not both.  
Frequency matching ensured that the characteristics of the population of controls 
are similar to the characteristics of the cases.  Controls and cases with previous 
diagnoses of other cancers were restricted from the dataset.  Due to privacy 
concerns from Medicaid and SHP, these groups were pooled and could not be 
analyzed separately.  A total of 1235 cases of kidney cancer and 3705 controls 
were identified.  All participants were given unique identification numbers to 
protect their anonymity.   
Statistical Analyses:  Conditional logistic regression was used to estimate the 
odds ratios of kidney cancer associated with antibiotic use overall, by antibiotic 
class, sex, and population type.  Calculating odds ratios by class of antibiotic 
allowed for ascertainment of additional cancer risk by type of antibiotic, as one 
class may be associated more strongly than another with a cancer outcome.  
Confounding and effect modification were evaluated for all geographical and 
demographic variables.  Furthermore, odds ratios were calculated separately by 
sex and population to examine any gender or geographic disparities that may 
have existed between the association between antibiotic usage and cancer 
outcomes.  The cancer outcome variable was categorical, either yes (1) or no (0), 
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while the predictor variables of days of antibiotic use or number of prescriptions 
were divided into categories of exposure.  Other covariates in the models 
included racial composition of census tract, and if the census tract was rural or 
urban, coastal or inland, and agricultural or industrial.  These were used as 
categorical variables in the multivariate analyses and were defined using the data 
sources and methods above.  Data retrieval, management, and analyses were 
performed using SAS version 9.3 (SAS Institute Inc., Cary, NC) and P < 0.05 was 
used to determine statistical significance. 
Results 
The total dataset included 4940 participants, comprised of 3705 controls 
and 1235 cases of kidney cancer.   The primary focus of these analyses was to 
assess the relationship between antibiotic usage and kidney cancer outcomes.  
Additional analyses including confounding and effect modification of 
demographic and geographic variables were performed to describe this 
relationship more completely.  The study had slightly more females than males 
but the composition was similar in respect to cases and controls.  More 
participants resided in census tracts composed of 0 to 33% black population, and 
again the break down was similar in regard to cases and controls.  In addition, 
most participants lived in agricultural versus industrial, inland versus coastal, and 
urban versus rural census tract types.  These percentages were mirrored in the 
composition of cases and controls (Table 1).  
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Increased risks between kidney cancer development and two different 
predictor variables, total number of prescriptions and total days of use of 
antibiotics, were utilized in this study.  These predictors were highly correlated, 
bearing a Pearson correlation coefficient of 0.83.  The relationship between the 
total number of antibiotic prescriptions and incident kidney cancer is displayed in 
Table 2.  A total of 12362 antibiotic prescriptions were dispensed to this study 
group and for the purpose of analysis were divided into tertiles; a 0 to 17 
prescriptions referent group, 18 to 131 prescriptions, and 132 and above.  An 
increase in cumulative number of prescriptions by participants showed 
statistically significant increased risks to the development of kidney cancer, after 
adjusting for age and length of enrollment in Medicaid or SHP.  Having been 
prescribed 18 to 131 prescriptions yielded an odds ratio of 1.50 (1.27 – 1.78) and 
having 132 and above carried an odds ratio of 1.43 (1.20 – 1.70).  Results were 
similar when examining the effect of the total number of days of antibiotic use in 
relation to kidney cancer (Table 3).  A total of 123588 days of use of antibiotics 
were reported in this dataset, and was also divided into tertiles for analysis.  An 
increase in risk for kidney cancer was found with increased levels of cumulative 
days of antibiotic usage.  The reference group used 0 to 115 total days of use, 
while the category of 116 to 950 days of use produced an odds ratio of 1.41 (1.20 
– 1.67), and the highest level of 951 and above days of antibiotic use yielded an 
OR of 1.46 (1.23 – 1.73).  In addition, categories for both total prescriptions and 
days of antibiotic use were analyzed by dividing the data into quartiles.  These 
analyses showed similar increased risks with higher levels of exposure as seen 
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with the tertile analysis described above.  Geographical and demographic 
variables from Table 1 were investigated for confounding and effect modification 
during these analyses, but had no effect on the association between antibiotic 
usage and kidney cancer.  
Further analyses were performed to investigate the additional risk 
provided by various classes of the most prescribed antibiotics in the dataset 
during the study period, both by total number of prescriptions and days of use.  
Six classes composed 81.3% of prescriptions in the dataset, 20.7% 
aminoglycosides, 19.1% quinolones, 16.9% cephalosporins, 14.4% penicillins, 
5.4% tetracyclines, and 4.9% sulfonamides.  Pearson correlation coefficients for 
each predictor variable for each class were high, 0.78 for prescriptions of 
aminoglycosides and days use of aminoglycosides, 0.94 for prescriptions and 
days of use of cephalosporins, 0.97 for penicillin predictors, 0.90 for quinolones, 
0.70 for tetracyclines, and 0.85 for sulfonamides.   Table 4 shows the association 
of kidney cancer development with the total number of prescriptions by antibiotic 
class.  Each class of antibiotic was divided into categories which reflected 
intrinsic breaks in the data, with 0 prescriptions for each class serving as the 
reference group.  However, participants with 0 prescriptions of a specific 
antibiotic class may still have prescriptions for one of the other 5 classes or a 
different antibiotic not included in these analyses.  This allowed for the 
determination of additional risk from these specific classes and did not restrict the 
dataset to those with 0 prescriptions of antibiotics for the entire study period, as 
this does not reflect current clinical prescribing patterns.  For aminoglycosides, 
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an increase in risk was seen for each level of exposure, 1.21 (1.01 – 1.45) for 1 
to 3 total prescriptions of aminoglycosides, 1.16 (0.93 – 1.43) for 4 to 85 
prescriptions, and 1.39 (1.12 – 1.73) for 86 or more prescriptions of 
aminoglycosides.  Only the lowest and highest levels of exposure were 
significant for this antibiotic class, the middle level of exposure was not 
significant.  Cephalosporins showed significant risk for 1 to 3 prescriptions with 
an OR of 1.26 (1.06 – 1.50) and 4 to 100 total prescriptions with an OR of 1.37 
(1.20 – 1.72).  The highest level of exposure for cephalosporins with greater than 
100 prescriptions was not significant at 1.12 (0.90 – 1.41).  Penicillins showed a 
significant increased risk of cancer for only the middle level of exposure, 3 to 30 
total penicillin prescriptions, with an OR of 1.24 (1.00 – 1.54).  The lowest level of 
1 to 2 prescriptions and highest level of greater than 30 prescriptions showed 
insignificant risk with ORs of 1.17 (0.98 – 1.39) and 1.03 (0.28 – 1.27), 
respectively.  The quinolones exhibited significant risk of kidney cancer for all 
levels of exposure, with an OR of 1.44 (1.02 – 1.71) for 1 to 2 total prescriptions, 
1.96 (1.62 – 2.37) for 3 to 30 prescriptions, and 1.61 (1.32 – 1.95) for greater 
than 30 total prescriptions.  No significance was found for increased additional 
risk from tetracyclines or sulfonamides.  Both classes of these antibiotics 
comprised the smallest percentages of the dataset, and therefore had only one 
level of exposure above the reference group.  The corresponding ORs for these 
classes were 1.19 (0.99 – 1.43) for 1 to 4738 total prescriptions of tetracyclines 
and 0.85 (0.64 – 1.13) for 1 to 3818 total sulfonamide prescriptions. 
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Exposure classified by days of use by antibiotic class and its association 
with kidney cancer risk is shown in Table 5.  Once again, levels of exposure were 
determined by natural breaks in the data, as well as clinical prescribing 
guidelines.  Zero days of use of the specific antibiotic in each analysis was used 
as reference, even though participants could have days of use of another 
antibiotic.  Aminoglycosides showed an elevated risk for the higher levels of 
exposure, 15 to 30 days of use and greater than 300 days of use with ORs of 
1.25 (1.02 – 1.53) and 1.33 (1.09 – 1.3), respectively.  The lowest level of 
exposure of 1 to 14 days of use was insignificant with an OR of 1.16 (0.94 – 
1.41).  The opposite trend was seen with cephalosporins, as the two lower 
categories of exposure showed significant risks with ORs of 1.28 (1.05 – 1.56) for 
1 to 14 days of use and 1.35 (1.10 – 1.67) for 15 to 400 days of use.  The highest 
level of exposure, greater than 400 days had an OR of 1.14 (0.93 – 1.40) and 
was not statistically significant.  The only risk provided by the use of penicillins 
was between 1 to 14 days with an OR of 1.03 – 1.53).  Using penicillins between 
15 and 150 days and more than 150 days did not show significant risks with ORs 
of 1.16 (0.95 – 1.41) and 1.02 (0.83 – 1.26).  The quinolones, as shown above 
with cumulative number of prescriptions, exhibited significant risks for each level 
of exposure.  The OR for use between 1 to 14 days was 1.38 (1.14 – 1.68), for 
15 to 35 days was 1.86 (1.50 – 2.31), for 36 to 400 days was 1.99 (1.61 – 2.46), 
and for greater than 400 days was 1.48 (1.20 – 1.83).  All of these risks were 
statistically significant.  Due to the smaller percentages of tetracyclines and 
sulfonamides in the dataset, these classes only had one level of exposure.  
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Neither of these antibiotic classes had a significant risk on the development of 
kidney cancer, as using tetracyclines for 1 to 71970 days provided an OR of 1.20 
(0.99 – 1.43) and using sulfonamides for 1 to 79891 days produced an OR of 
0.85 (0.64 – 1.13).  We further investigated confounding and interaction by 
geographical variables, but did not uncover any effects from these variables. 
Discussion 
Antibiotic usage was positively associated with kidney cancer, in terms of 
both the total number of antibiotic prescriptions given to a patient and the total 
number of days of use of antibiotics.  Using case-control methodology, we found 
that kidney cancer cases had higher exposures to both measures of antibiotic 
use than controls after multivariate adjustment, although not necessarily in a 
dose response manner.  These findings were robust for both tertile and quartile 
exposure analysis.  Furthermore, our findings suggested that specific classes of 
antibiotics at varying levels of exposure can pose as a risk factor for kidney 
cancer outcomes, but once again, not necessarily in a dose response manner.  
For aminoglycosides, cephalosporins, and penicillins, it is evident that only some 
levels of exposure led to increased risks, this may result from cellular 
mechanisms of drug absorption or processing that is only present at certain 
concentrations of drugs, or maybe even the sequential timing between the 
prescribing of these antibiotics.  Varying modes of actions of these classes may 
also contribute to the differential risk they provide based on how they affect host 
immune and inflammatory responses and metabolism and byproducts of 
gastrointestinal bacteria (2;3).   It is important to note that the quinolones showed 
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increased risks for all categories of exposure with both total prescriptions and 
days of use, and these can be described as the class of antibiotics which carry 
the most risk for kidney cancers in this study.  Tetracyclines and sulfonamides 
were not prescribed in high amounts in this dataset, and separate analysis 
focusing on these two classes may be needed to tease out their real association 
with cancer development. 
Results from our study are in accordance with studies by Knekt et al and 
Velicer et al which examined the risk of antibiotic usage in relation to breast 
cancer.  However, the Knekt study was a cohort study and only investigated 
antibiotic usage in response to urinary tract infections as a risk for cancer, while 
our case-control study did not have the restriction of antibiotics prescribed for 
certain types of infections.  In this way, we studied antibiotic usage as the sole 
risk factor and not the original infections.  While they did find increased risk 
associated with antibiotic usage and breast cancer, this study was limited to 
premenopausal women who received antibiotics for a urinary tract infection, while 
our study finds risk in men and women of various ages who were prescribed 
antibiotics for varying conditions. While they did uncover a weak association 
between the types of region in which these women resided, urban, agricultural, or 
industrial areas, this study could not confirm those findings.  Nor could our study 
detect an association between antibiotic usage and cancer from living in coastal 
or inland areas. 
The conclusions from our study also agree with the results from the 
Velicer et al study.  Both studies found that antibiotic usage is a significant risk 
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factor for cancer development.  While the study by Velicer detected risks posed 
by all major antibiotics classes in their dataset for total prescriptions and days of 
use, we did not find these same risks for all of the most common antibiotics in our 
dataset.  It is important to note that our dataset represented different antibiotics 
than those in the Velicer study.  For example, the quinolones were not commonly 
dispensed in the Velicer dataset and so were not included in their analyses.  
Velicer et al also noticed this risk for fatal breast cancers as well as incident 
breast cancers.  Our study differs from the Velicer study because their study 
included only women, as it was primarily a breast cancer study.  Also, our study 
only included incident cases of kidney cancer, we did not study fatal cases of 
kidney cancer.   
The foremost limitation in this study is that even though antibiotic were 
prescribed to participants, there is no way of knowing if the prescriptions were 
actually filled or administered correctly, for example at the right times and for the 
full course of treatment.  Inpatient use of antibiotics was not factored into this 
study because we did not want the primary reason for hospitalization to be 
considered a risk factor for cancer development.  Furthermore, this analysis did 
not take into account the timing between multiple antibiotic courses.  Additional 
studies need to be performed to examine if risk increases from shorter time 
intervals between antibiotic courses versus longer intervals.  Another limitation is 
that, even though both SHP and Medicaid enrollees were included in this study, 
we could not determine risks for individuals in each health plan separately.  In 
addition, there was no data about other risk factors for kidney cancer or renal 
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pelvic cancers, such as genetic disposition or smoking and alcohol consumption.  
Residual confounding by socioeconomic status may also be influencing these 
results, but was not directly addressed in these analyses. 
The strengths of this study include the unique linkage between Medicaid 
and SHP data administrative claims to data from SCCCR.  This allowed for the 
accurate determination of pharmacy records for participants and the lack of recall 
bias as no interviews had to be performed to obtain exposure status.  Data were 
complete for antibiotic prescriptions, including drug names, National Drug Codes, 
American Hospital Formulary System information, days supplied, and number of 
prescriptions for each class of antibiotic.  Also, by linking to a disease registry, 
we had a defined cohort from which cases could be chosen, along with the 
demographic data and detailed cancer information which comes from SCCCR.  
We did not include individuals who switched from one health plan to another, as 
a participant had to be enrolled continuously in either plan to be eligible for this 
study.  This avoided missing data from periods of time with no insurance 
coverage or before switching to a different plan.  As a whole, this study 
addresses risk for kidney cancer development in relation to antibiotic usage in a 
wider population, both men and women, in various regions in the state of South 
Carolina, allowing for greater external validity of our findings.  Drug metabolism 
pathways were also considered in this study, as the kidneys are vital in the 
processing, break down, and excretion of antibiotics.  Therefore, these organs 
should be closely monitored and studied as a site for cancer development in light 
of use, overuse, and misuse of antibiotics.  As exposure levels increase, this 
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study aimed to divide the data into appropriate sample sizes for each category, 
providing more powerful results.  The fact that cumulative exposure results could 
be repeated by dividing the data into quartiles, as well as tertiles, lends credence 
to these findings.  Lastly, our findings were confirmed with an adequate sample 
size for this case-control study, with 3705 controls and 1235 cases.   
In conclusion, we uncovered evidence which suggests that the use of 
antibiotics is linked to the development of kidney and renal pelvic cancers, 
however, further epidemiological and biological studies must be conducted to 
verify these effects.  These results were consistent for all levels of exposure for 
total number of prescriptions and days of use during this study period, which 
provided strong associations.  While the days of use covariate provided 
increasing risk for increasing use, total prescriptions did not, indicating that days 
of antibiotic exposure is more strongly related to cancer outcomes.  Conversely, 
higher doses of antibiotics may not increase risk, but overall use and exposure 
may be enough to lead to cancer.  Moreover, certain classes of antibiotics at 
varying levels of exposure can also contribute to cancer development.  There 
was also consistency in our findings due to their agreement with other studies 
performed in various parts of the world with varying populations.    Clinically, 
these findings caution the prescribing of unneeded antibiotics as well as reducing 
the exposure to antibiotics in generally healthy adult patients.  While this class of 
drugs has proven its effectiveness and advantages over the past decades, a 
detrimental side to them may exist as well, and in the mean time, they should be 
administered only with great carefulness and prudence. 
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Table 6.1.  Descriptive Characteristics of Controls and Kidney Cancer 
Cases* 
Characteristic All Participants 
(n = 4940) 
Controls 
(n = 3705) 
Cases 
(n = 1235) 
Tertiles of Antibiotic Exposure by Total Number of Prescriptions 
0 – 17 1645 (33.3%) 1302 (35.1%) 343 
(27.8%) 
18 – 131 1618 (32.8%) 1170 (31.6%) 448 
(36.3%) 
132 – 12362 1677 (34.0%) 1233 (33.3%) 444 
(35.9%) 
Tertiles of Antibiotic Exposure by Total Days of Use 
0 – 115 1632 (33.0%) 1289 (34.8%) 343 
(27.8%) 
116 – 950 1629 (33.0%) 1192 (32.2%) 437 
(35.4%) 
951 – 123588 1679 (34.0%) 1224 (33.0%) 455 
(36.8%) 
Sex    
Female 2824 (57.2%) 2173 (58.7%) 651 
(52.7%) 
Male 2116 (42.8%) 1532 (41.3%) 584 
(47.3%) 
Racial Composition of Census Tract 
0 – 33% Black 3006 (60.9%) 2340 (63.2%) 666 
(53.9%) 
34 – 66% Black 1366 (27.7%) 960 (25.9%) 406 
(32.9%) 
67 – 100% Black 568 (11.4%) 405 (10.9%) 163 
(13.2%) 
Agricultural/Industrial Census Tract 
Agricultural 3163 (66.4%) 2337 (66.0%) 826 
(67.4%) 
Industrial 1604 (33.6%) 1204 (34.0%) 400 
(32.6%) 
Coastal/Inland Census Tract 
Coastal 1079 (22.6%) 787 (22.2%) 292 
(23.8%) 
Inland 3688 (77.4%) 2754 (77.8%) 934 
(76.2%) 
Urban/Rural Census Tract 
Rural 1909 (40.1%) 1391 (39.3%) 518 
(42.3%) 
Urban 2858 (59.9%) 2150 (60.7%) 708 
(57.7%) 
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 *Data were complete for exposures and sex and racial composition of census 
tracts.  Missing data for all other variables include 173 (3.5%) total missing, 164 
controls (4.4%) and 9 cases (0.7%).  Variable stratum numbers may not equal 
total number of cases or controls due to these missing data. 
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Table 6.2.  Relationship Between Incident Kidney Cancer and Total Number 
of Prescriptions 
Number of 
Prescriptions 
Controls 
(n = 3705) 
Cases 
(n = 1235) 
OR (95% CI) P value 
for Trend 
0 – 17 1302 (35.1%) 343 (27.8%) Reference  
<.0001 18 – 131 1170 (31.6%) 448 (36.3%) 1.50 (1.27 – 
1.78) 
132 - 12362 1233 (33.3%) 444 (36.0%) 1.43 (1.20 – 
1.69) 
Abbreviations:  OR = odds ratio; CI = confidence interval.   
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Table 6.3.  Relationship Between Incident Kidney Cancer and Total Days of 
Antibiotic Use 
Number of 
Days of 
Antibiotic 
Use 
Controls 
(n = 3705) 
Cases 
(n = 1235) 
OR (95% CI) P value 
for Trend 
0 – 115 1289 (34.8%) 343 (27.8%) Reference  
<.0001 116 – 950 1192 (32.2%) 437 (35.4%) 1.41 (1.20 – 
1.67) 
951 – 123588 1224 (33.0%) 455 (36.8%) 1.46 (1.23 – 
1.73) 
Abbreviations:  OR = odds ratio; CI = confidence interval.   
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Table 6.4.  Relationship between Incident Kidney Cancer and Total Number 
of Prescriptions by Antibiotic Class* 
Number of 
PrescriptionsE 
Controls 
(n = 3705) 
Cases 
(n = 1235) 
OR (95% CI) P value 
for 
Trend 
Aminoglycosides     
 
0.0084 
0 2412 (65.1%) 744 (60.2%) Reference 
1 – 3 566 (15.3%) 209 (16.9%) 1.21 (1.01 – 1.45) 
4 – 85 375 (10.1%) 133 (10.8%) 1.16 (0.93 – 1.43) 
≥86 352 (9.5%) 149 (12.1%) 1.39 (1.12 – 1.73) 
Cephalosporins     
 
0.0064 
0 2517 (67.9%) 777 (62.9%) Reference 
1 – 3 577 (15.6%) 224 (18.1%) 1.26 (1.06 – 1.50) 
4 – 100 285 (7.7%) 121 (9.8%) 1.37 (1.20 – 1.72) 
≥101 326 (8.8%) 113 (9.2%) 1.12 (0.89 – 1.41) 
Penicillins     
 
0.1163 
0 2326 (62.8%) 737 (59.7%) Reference 
1 – 2 594 (16.0%) 220 (17.8%) 1.17 (0.98 – 1.39) 
3 – 30 366 (9.9%) 143 (11.6%) 1.24 (1.00 – 1.54) 
≥31 419 (11.3%) 135 (10.9%) 1.03 (0.83 – 1.27) 
Quinolones     
 
<.0001 
0 2197 (59.3%) 589 (47.7%) Reference 
1 – 2 634 (17.1%) 239 (19.4%) 1.44 (1.02 – 1.71) 
3 – 30 430 (11.6%) 220 (17.8%) 1.96 (1.62 – 2.37) 
≥31 444 (12.0%) 187 (15.1%) 1.61 (1.32 – 1.95) 
Tetracyclines     
0.0664 0 3212 (86.7%) 1045 (84.6%) Reference 
1 – 4738 493 (13.3%) 190 (15.4%) 1.19 (0.99 – 1.43) 
Sulfonamides     
0.2604 0 3469 (93.6%) 1167 (94.5%) Reference 
1 – 3818 236 (6.4%) 68 (5.5%) 0.85 (0.64 – 1.13) 
Abbreviations:  OR = odds ratio; CI = confidence interval.  *The reference group 
for these analyses includes cases and controls with zero prescriptions of the 
specific antibiotic class in question during the regression.  However, these 
participants may have had prescriptions for one of the other antibiotic classes in 
these analyses or an antibiotic which was not represented above.  ‡Representing 
the 6 most prescribed antibiotic classes in the dataset (81.3% of all antibiotic 
prescriptions). 
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Table 6.5.  Relationship between Incident Kidney Cancer and Total Days of 
Use by Antibiotic Class* 
Number of 
Days of 
Antibiotic UseE 
Controls 
(n = 3705) 
Cases 
(n = 1235) 
OR (95% CI) P value 
for Trend 
Aminoglycosides     
 
0.0113 
0 2413 (65.1%) 744 (60.2%) Reference 
1 – 14 455 (12.3%) 160 (13.0%) 1.16 (0.94 -1.41) 
15 – 300 418 (11.3%) 161 (13.0%) 1.25 (1.02 – 1.53) 
≥301 419 (11.3%) 170 (13.8%) 1.33 (1.09 – 1.63) 
Cephalosporins     
 
0.0064 
0 2518 (68.0%) 777 (62.9%) Reference 
1 – 14 420 (11.3%) 165 (13.4%) 1.28 (1.05 -1.56) 
15 – 400 349 (9.4%) 146 (11.8%) 1.35 (1.10 – 1.67) 
≥401 418 (11.3%) 147 (11.9%) 1.14 (0.93 – 1.40) 
Penicillins     
 
0.0885 
0 2328 (62.8%) 738 (59.8%) Reference 
1 – 14 431 (11.6%) 172 (13.9%) 1.26 (1.03 – 1.53) 
15 – 150 487 (13.1%) 178 (14.4%) 1.16 (0.95 – 1.41) 
≥151 459 (12.4%) 147 (11.9%) 1.02 (0.83 – 1.26) 
Quinolones     
 
<.0001 
0 2198 (59.3%) 589 (47.7%) Reference 
1 – 14 483 (13.0%) 176 (14.3%) 1.38 (1.14 – 1.68) 
15 – 35 323 (8.7%) 156 (12.6%) 1.86 (1.50 – 2.31) 
36 – 400 328 (8.9%) 169 (13.7%) 1.99 (1.61 – 2.46) 
≥401 373 (10.1%) 145 (11.7%) 1.48 (1.20 – 1.83) 
Tetracyclines     
0.0664 0 3212 (86.7%) 1045 (84.6%) Reference 
1 – 71970 493 (13.3%) 190 (15.4%) 1.19 (0.99 – 1.43) 
Sulfonamides     
0.2604 0 3469 (93.6%) 1167 (94.5%) Reference 
1 – 79891 236 (6.4%) 68 (5.5%) 0.85 (0.64 – 1.13) 
Abbreviations:  OR = odds ratio; CI = confidence interval.  *The reference group 
for these analyses includes cases and controls with zero prescriptions of the 
specific antibiotic class in question during the regression.  However, these 
participants may have had prescriptions for one of the other antibiotic classes in 
these analyses or an antibiotic which was not represented above.  ‡Representing 
the 6 most prescribed antibiotic classes in the dataset (81.3% of all antibiotic 
prescriptions).
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CHAPTER 7 
Conclusion 
Collectively, the findings from this study show that antibiotic usage is 
related to ARI and kidney cancer outcomes in South Carolina.  Looking at 
relative risk ratios from our study, our findings indicate significant differences in 
outcomes of antibiotic resistant infections, liver cancers, and kidney cancers by 
antibiotic exposure and census tract types.  Predictably, antibiotic exposure is 
associated with ARI outcomes.  However, higher percentages of black 
populations are also associated with an increase in ARI outcomes.  This effect is 
also seen when investigating liver cancer outcomes, but antibiotic exposure has 
no influence over liver cancer development.  Kidney cancer is associated with 
higher levels of antibiotic exposure, residing in a rural census tract, as well as 
with higher percentages of black populations in the tract. 
While it has been established that increased antibiotic use leads to the 
emergence of ARIs (12-15), this trend has not been investigated on a 
background of geographical and demographic differences.  However, this only 
seems natural as differential prescribing patterns in various region types have 
been uncovered in previous studies (16;17).  Our results show that the mean 
antibiotic prescriptions do vary based on geographical census tract type, as 
agricultural, inland, and rural areas receive more prescriptions, but this does not 
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necessarily translate to increased risks for ARIs, or even liver or kidney cancers.  
From the RRs in this study, we have confirmed that antibiotic exposure is 
associated with ARI outcomes, but that geographical factors of the census tracts 
do not influence this association.  However, demographics do influence this 
relationship as higher black populations show increased risk of ARI when 
adjusted for total number of prescriptions.    
Because of the hypotheses and studies by Setchell, Knekt, and Velicer, 
antibiotic usage in relationship to cancer is now also an avenue that requires 
examination.  Metabolic pathways allow the liver and kidneys the most exposure 
to antibiotics in the body, and therefore make these organs more at risk for 
developing toxicities and cancers.  This was seen in our analysis for kidney 
cancer, but not for liver cancer.   It may be that the kidneys’ continuous filtering 
and concentration of antibiotics in urine provides the kidney with more potent and 
constant exposure to antibiotic compounds in the body than the liver, leading to 
an increased risk in one organ but not the other.  In addition to antibiotic 
exposure and racial composition, rural and urban designations of the census 
tract affect kidney cancer outcomes.  Urban tracts carry a decreased risk for 
kidney cancer outcomes when adjusted for the other variables in the model.  In 
this case, it is also important to remember antibiotic exposures from 
environmental sources, for example rural census tracts are exposed to antibiotics 
in runoff from farms in which animals are treated with antibiotics, as well as 
airborne and waterborne exposure from orchards in which fruiting trees are 
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sprayed with antibiotics.  This increased environmental exposure can also 
influence the relationship between kidney cancer and antibiotic usage. 
Furthermore, our findings suggest higher risks of ARIs, liver, and kidney 
cancer outcomes in tracts with higher percentages of black population, 
specifically 67 to 100% of the population.  This may be due to socioeconomic 
statuses of these tracts, as areas such as these may be more rural and less 
likely to have routine access to health care, resulting in undesirable outcomes.  In 
addition, less routine access to healthcare may actually increase antibiotic 
exposure, as doctors would be more willing to prescribe antibiotics for a patient 
who cannot easily come back for a follow up appointment.  This difference may 
even indicate a biological or physiological phenomenon in which African 
Americans are unable to metabolize antibiotics as efficiently or completely as 
Caucasian populations, thus leading to these outcomes.  This type of dissimilarity 
between ethnicities is not unheard of, as it has been found that Asian and Native 
American populations do not possess all of the functional and active enzymes to 
metabolize alcohol as efficiently as Caucasians, and that this may lead to the 
undesirable outcome of alcoholism (31;32).  
These results indicate that antibiotic usage is a risk factor for the 
development of antibiotic resistant bacterial infections and kidney cancers and 
that these risks can be magnified based on the types of census tracts in which 
people live.  Various characteristics of these tracts may lead to these increased 
risks, including environmental exposures to antibiotics, regular access to health 
care, and genetic dispositions of the populations in these tracts.  Our findings 
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agree with the studies which show that antibiotics use is a major cause of 
resistance by bacteria and subsequent resistant infections (12-15), and in part, 
with studies by Knekt and Velicer, which show increased risks from antibiotics for 
breast cancer.  Here, we found that kidney cancer is associated with antibiotic 
usage, but liver cancer is not.  Although the Knekt study briefly assessed these 
risks by urban, agricultural, and rural types, this study’s region types were more 
varied and inclusive, relying on geocoded data and defined criteria for region 
types.  The Velicer study did not address the effect of various region types.  Also, 
both the Knekt and Velicer study focused on breast cancer in women, while our 
methods focused on both men and women at risk for liver and kidney cancers.   
As an ecological study, there are limitations to these results.  Temporality 
cannot be accurately determined with this study, as there was no time line 
between antibiotic exposure and the disease outcome, so a proper cause and 
effect situation cannot be outlined.  As aggregate data and because our smallest 
unit of analysis is the census tract, risks at an individual level cannot be 
assessed.  At an individual level, the risks uncovered in this study may exist on a 
different scale or may not exist at all.  Additionally, confounding at an individual 
level cannot be assessed with this type of study and analysis.  
Strengths of this study include the linkage between SHP and Medicaid 
claims data with SCCCR data to ascertain and confirm the diagnoses of liver and 
kidney cancers in the population.  The claims data from SHP and Medicaid 
provided a relatively easy and inexpensive way to ascertain ARI diagnoses and 
the drug files allowed accurate antibiotic exposure data as well. This study was 
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ideal for determining the rudimentary relationship between antibiotic usage and 
ARI, liver cancer, and kidney cancer outcomes in relation to census tract types, 
and offers hypotheses and conclusions for further exploration and investigation.  
From our study, it is important to now look at antibiotic usage not only as a whole 
but against the background of varying geographical and demographic factors, 
and to realize that antibiotics do have a role in unwanted and potentially fatal 
outcomes.  Further targeted studies using case-control or cohort methodology 
would be the next step in identifying and describing an accurate relationship 
between antibiotic usage, negative outcomes, and prescribing patterns and 
geographical areas in South Carolina. 
Findings from this aim showed that antibiotic usage is not a risk factor for 
the development of liver cancer, as none of the ORs were statistically significant.  
The relationship between exposure and outcome, however, was confounded by 
sex when total number of prescriptions was used as the exposure variable or 
was effect modified when total days of use of antibiotics was used as the 
exposure variable during analysis.  Specific classes of antibiotics were also 
investigated as potential cancer risks, both by total numbers of prescriptions and 
total days of use.  Again, these results were not statistically significant and 
cannot be established as risks for liver cancer outcomes. 
Several differences in the analyses were noted when using each predictor 
variable.  When using total number of prescriptions as the exposure, sex was a 
positive confounder, resulting in a shift away from the null from the crude OR 
estimates.  Sex itself is already a documented risk factor for liver cancer, as men 
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are at least 2.4 times more likely than women to develop these cancers (17).  
However, when using days of antibiotic use, sex was an effect modifier, resulting 
in different risk estimates for males and females at each level of exposure.  Even 
though sex was also a positive confounder in these analyses, the significance of 
the interaction term points towards effect modification as a major player in this 
association.  Effect modification by sex for cancer outcomes have been 
described previously in the context of alcohol consumption and renal cell 
carcinomas, resulting in lower risks of cancer with increased alcohol consumption 
in women, due in part to differences in alcohol and estrogen metabolism in 
women (23).  In this study, our two predictor variables are highly correlated, but 
the days of use variable is more subjective.  For example, men may follow the 
allotted course of antibiotics and thus receive more exposure than females who 
may cut the course of treatment short, or vice versa.  This could result in the 
different risk estimates for each group as the exposure levels are changing.  
Total number of prescriptions does not rely on the behaviors of patients, but is 
reflected as a doctor prescribed constant variable. 
Another difference between the analyses using these two predictors is 
effect modification by demographic variables.  For total prescriptions, only a 
coastal or inland census tract was a potential effect modifier, but for days of 
antibiotic use, in addition to sex, coastal or inland census tracts and agricultural 
or industrial census tracts were effect modifiers.  Generally, living in a coastal 
and agricultural census tract provided greater risk.  This could be due to the 
greater environmental exposure to antibiotics in these regions, for example from 
 151 
waste water runoff in coastal tracts and farming and veterinary use in agricultural 
tracts (18-22).  Further research needs to be conducted to take into account this 
environmental exposure as a significant risk for the development of cancer 
outcomes.   
Analyses by total prescriptions by classes of antibiotics did not result in 
increased risks of liver cancer from cephalosporins, penicillins, quinolones, 
macrolides, miscellaneous antibacterials, and tetracyclines.  Further analysis 
using days of use was also carried out and led to identical results to those in 
Table 7.  Due to the insufficient numbers in each level, we were unable to 
properly assess risks across varying exposure levels.   In the future, with a larger 
dataset, more levels of exposure can be teased out, therefore leading to a better 
resolution for detecting these associations by each predictor.        
Findings from this aim agree with those from the Knekt et al study.  While 
we detected increased risks from antibiotic usage for liver cancer, our findings 
were also not always statistically significant, as with the Knekt findings.  
However, the Knekt study was a cohort study which only investigated antibiotic 
usage in response to urinary tract infections as a risk for cancer, while our case-
control study did not have the restriction of antibiotics prescribed for certain types 
of infections.  By doing so, we studied antibiotic usage as the sole risk factor and 
not the original infections.  While they did find increased risk associated with 
antibiotic usage and breast cancer, this was displayed in premenopausal women 
who received antibiotics for a urinary tract infection, our study indicates that this 
risk is present in men and women of various ages who were prescribed 
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antibiotics for varying conditions. While they did uncover a weak protective 
association between agricultural and industrial areas compared to urban centers, 
this study found that coastal and agricultural regions bore greater risks for liver 
cancer with antibiotic use as an exposure.  
However, the conclusions from this aim did not agree with the results from 
the Velicer et al study.  The Velicer study noted significant risks from antibiotic 
usage for liver cancer, but our finding were not significant.   While the study by 
Velicer detected risks posed by all major antibiotics classes in their dataset for 
total prescriptions and days of use, we did not find these same risks for any of 
the most common antibiotics in our dataset.  Our study differs from the Velicer 
study as well because their study included only women, as it was primarily a 
breast cancer study.  Also, our study only included incident cases of liver cancer, 
we did not study fatal cases of liver cancer.  We further investigated confounding 
and interaction by demographic and geographical variables, and uncovered 
these effects in our study. 
The foremost limitation in this study is that even though antibiotics were 
prescribed to participants, there is no way of knowing if the prescriptions were 
actually filled or administered correctly, for example at the right times and for the 
full course of treatment.  Inpatient use of antibiotics was not factored into this 
study.  Furthermore, this analysis did not take into account the timing between 
multiple antibiotic courses.  Additional studies need to be performed to examine if 
risk increases from shorter time intervals between antibiotic courses versus 
longer intervals.  In addition, there was no data about other risk factors for liver 
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cancer or hepatic carcinomas, such as genetic disposition or smoking and 
alcohol consumption.  Residual confounding by socioeconomic status may also 
be influencing these results, but was not directly addressed in these analyses.  
Furthermore, due to the small sample size of this study, it was difficult to detect 
an association between exposure and outcome.  Repeated analyses with a 
larger sample size may yield more consistent findings with those of Velicer. 
The strengths of this study include the unique linkage between Medicaid 
and SHP data administrative claims to data from SCCCR.  This allowed for the 
accurate determination of pharmacy records for participants and the lack of recall 
bias as no interviews had to be performed to obtain exposure status.  Data were 
complete for antibiotic prescriptions, including drug names, National Drug Codes, 
American Hospital Formulary System information, days supplied, and number of 
prescriptions for each class of antibiotic.  Also, by linking to a disease registry, 
we had a defined cohort from which cases could be chosen, along with the 
demographic data and detailed cancer information which comes from SCCCR.  
We did not include individuals who switched from one health plan to another, as 
a participant had to be enrolled continuously in either plan to be eligible for this 
study.  This avoided missing data from periods of time with no insurance 
coverage or before switching to a different plan.  As a whole, this study 
addresses risks for liver cancer development in relation to antibiotic usage in a 
wider population, both men and women, in various regions in the state of South 
Carolina, allowing for greater generalizability of this study’s findings.  Drug 
metabolism pathways were also considered in this study, as the liver is the main 
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organ in the body responsible for metabolizing, processing and breaking down of 
antibiotics.  Therefore, this organ should be closely monitored and studied as a 
site for cancer development in light of use, overuse, and misuse of antibiotics.  
As exposure levels increase, this study aimed to divide the data into appropriate 
sample sizes for each category, providing more powerful results.  The fact that 
cumulative exposure results could be repeated by dividing the data into quintiles, 
as well as quartiles, lends credibility to these findings. 
We did not uncover evidence to suggest that the use of oral antibiotics is 
associated with the development of liver cancer.  These results suggest that 
demographic and geographical variables may influence this relationship, but 
further analyses with a larger sample size are needed to accurately describe this 
association.  In addition, specific classes of antibiotics were not shown to be 
more associated with cancer outcomes than others.  Clinically, these findings are 
not pertinent.  Yet in light of findings from previous studies and the toxic nature of 
antibiotics, safer prescribing of antibiotics as well as reducing the exposure to 
antibiotics in the generally healthy adult population seems prudent.  While this 
family of drugs has proven its effectiveness and advantages over the past 
decades, recent medicine has been negatively affected by their use, including 
the emergence of resistant bacterial infections, and now as a potential risk factor 
for cancers. 
Antibiotic usage was positively associated with kidney cancer, in terms of 
both the total number of antibiotic prescriptions given to a patient and the total 
number of days of use of antibiotics.  Using case-control methodology, we found 
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that kidney cancer cases had higher exposures to both measures of antibiotic 
use than controls after multivariate adjustment, although not necessarily in a 
dose response manner.  These findings were robust for both tertile and quartile 
exposure analysis.  Furthermore, our findings suggested that specific classes of 
antibiotics at varying levels of exposure can pose as a risk factor for kidney 
cancer outcomes, but once again, not necessarily in a dose response manner.  
For aminoglycosides, cephalosporins, and penicillins, it is evident that only some 
levels of exposure led to increased risks, this may result from cellular 
mechanisms of drug absorption or processing that is only present at certain 
concentrations of drugs, or maybe even the sequential timing between the 
prescribing of these antibiotics.  Varying modes of actions of these classes may 
also contribute to the differential risk they provide based on how they affect host 
immune and inflammatory responses and metabolism and byproducts of 
gastrointestinal bacteria (2;3).   It is important to note that the quinolones showed 
increased risks for all categories of exposure with both total prescriptions and 
days of use, and these can be described as the class of antibiotics which carry 
the most risk for kidney cancers in this study.  Tetracyclines and sulfonamides 
were not prescribed in high amounts in this dataset, and separate analysis 
focusing on these two classes may be needed to tease out their real association 
with cancer development. 
Results from our study are in accordance with studies by Knekt et al and 
Velicer et al which examined the risk of antibiotic usage in relation to breast 
cancer.  However, the Knekt study was a cohort study and only investigated 
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antibiotic usage in response to urinary tract infections as a risk for cancer, while 
our case-control study did not have the restriction of antibiotics prescribed for 
certain types of infections.  In this way, we studied antibiotic usage as the sole 
risk factor and not the original infections.  While they did find increased risk 
associated with antibiotic usage and breast cancer, this study was limited to 
premenopausal women who received antibiotics for a urinary tract infection, while 
our study finds risk in men and women of various ages who were prescribed 
antibiotics for varying conditions. While they did uncover a weak association 
between the types of region in which these women resided, urban, agricultural, or 
industrial areas, this study could not confirm those findings.  Nor could our study 
detect an association between antibiotic usage and cancer from living in coastal 
or inland areas. 
The conclusions from our study also agree with the results from the 
Velicer et al study.  Both studies found that antibiotic usage is a significant risk 
factor for cancer development.  While the study by Velicer detected risks posed 
by all major antibiotics classes in their dataset for total prescriptions and days of 
use, we did not find these same risks for all of the most common antibiotics in our 
dataset.  It is important to note that our dataset represented different antibiotics 
than those in the Velicer study.  For example, the quinolones were not commonly 
dispensed in the Velicer dataset and so were not included in their analyses.  
Velicer et al also noticed this risk for fatal breast cancers as well as incident 
breast cancers.  Our study differs from the Velicer study because their study 
included only women, as it was primarily a breast cancer study.  Also, our study 
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only included incident cases of kidney cancer, we did not study fatal cases of 
kidney cancer.   
The foremost limitation in this study is that even though antibiotic were 
prescribed to participants, there is no way of knowing if the prescriptions were 
actually filled or administered correctly, for example at the right times and for the 
full course of treatment.  Inpatient use of antibiotics was not factored into this 
study because we did not want the primary reason for hospitalization to be 
considered a risk factor for cancer development.  Furthermore, this analysis did 
not take into account the timing between multiple antibiotic courses.  Additional 
studies need to be performed to examine if risk increases from shorter time 
intervals between antibiotic courses versus longer intervals.  Another limitation is 
that, even though both SHP and Medicaid enrollees were included in this study, 
we could not determine risks for individuals in each health plan separately.  In 
addition, there was no data about other risk factors for kidney cancer or renal 
pelvic cancers, such as genetic disposition or smoking and alcohol consumption.  
Residual confounding by socioeconomic status may also be influencing these 
results, but was not directly addressed in these analyses. 
The strengths of this study include the unique linkage between Medicaid 
and SHP data administrative claims to data from SCCCR.  This allowed for the 
accurate determination of pharmacy records for participants and the lack of recall 
bias as no interviews had to be performed to obtain exposure status.  Data were 
complete for antibiotic prescriptions, including drug names, National Drug Codes, 
American Hospital Formulary System information, days supplied, and number of 
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prescriptions for each class of antibiotic.  Also, by linking to a disease registry, 
we had a defined cohort from which cases could be chosen, along with the 
demographic data and detailed cancer information which comes from SCCCR.  
We did not include individuals who switched from one health plan to another, as 
a participant had to be enrolled continuously in either plan to be eligible for this 
study.  This avoided missing data from periods of time with no insurance 
coverage or before switching to a different plan.  As a whole, this study 
addresses risk for kidney cancer development in relation to antibiotic usage in a 
wider population, both men and women, in various regions in the state of South 
Carolina, allowing for greater external validity of our findings.  Drug metabolism 
pathways were also considered in this study, as the kidneys are vital in the 
processing, break down, and excretion of antibiotics.  Therefore, these organs 
should be closely monitored and studied as a site for cancer development in light 
of use, overuse, and misuse of antibiotics.  As exposure levels increase, this 
study aimed to divide the data into appropriate sample sizes for each category, 
providing more powerful results.  The fact that cumulative exposure results could 
be repeated by dividing the data into quartiles, as well as tertiles, lends credence 
to these findings.  Lastly, our findings were confirmed with an adequate sample 
size for this case-control study, with 3705 controls and 1235 cases.   
In conclusion, we uncovered evidence which suggests that the use of 
antibiotics is linked to the development of kidney and renal pelvic cancers, 
however, further epidemiological and biological studies must be conducted to 
verify these effects.  These results were consistent for all levels of exposure for 
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total number of prescriptions and days of use during this study period, which 
provided strong associations.  While the days of use covariate provided 
increasing risk for increasing use, total prescriptions did not, indicating that days 
of antibiotic exposure is more strongly related to cancer outcomes.  Conversely, 
higher doses of antibiotics may not increase risk, but overall use and exposure 
may be enough to lead to cancer.  Moreover, certain classes of antibiotics at 
varying levels of exposure can also contribute to cancer development.  There 
was also consistency in our findings due to their agreement with other studies 
performed in various parts of the world with varying populations.    Clinically, 
these findings caution the prescribing of unneeded antibiotics as well as reducing 
the exposure to antibiotics in generally healthy adult patients.  While this class of 
drugs has proven its effectiveness and advantages over the past decades, a 
detrimental side to them may exist as well, and in the mean time, they should be 
administered only with great carefulness and prudence. 
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